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Metazoans regulate histone protein synthesis with DNA replication in S-phase via 
post-transcriptional modification of the histone mRNAs, which see a 30-fold increase in 
expression at the beginning of S-phase. Histone mRNAs are the only mRNAs that do not end 
in polyadenylation, but instead in a conserved stemloop. This stemloop, along with Stemloop 
Binding Protein (SLBP), are required for the unique pathway for histone mRNA processing, 
translation, and degradation. The stemloop also serves to bind 3’ histone exonuclease 
(3’hExo), which removes 2nt from the 3’ termini, leaving the stemloop and a 3nt tail. 
Previous work has shown that if 3’hExo degrades too far past those 2nt, a uridyl transferase 
(TUT7) will add nontemplated uridines to compensate length back to 3nt past the stemloop. 
This oligouridylation serves to maintain a proper length for stable histone mRNAs along with 
longer uridine tails (3+nt) being found during degradation of the histone mRNA. In this 
thesis, I have refined a deep sequencing strategy to study the 3’ termini of histone mRNA 
molecules with a single nucleotide resolution of non-templated nt additions. I have also 
generated CRISPR mediated Knock Out (KO) human cancer cell lines for both TUT7 and 
3’hExo. I have analyzed these KO cells with the above deep sequencing strategy, along with 
flow cytometry and molecular biology, to demonstrate that both 3’hExo and TUT7 are 
essential to regulating the 3’ termini of stable histone mRNA molecules. I also demonstrate 
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that 3’hExo is involved in initiation of histone mRNA degradation, and that TUT7 helps 
initiate and progress 3’ to 5’ degradation of histone mRNA. I also demonstrate with flow 
cytometry and northern blots that 3’hExo KO cells have delayed mitosis, along with inhibited 
histone mRNA degradation; and TUT7 KO cells have normal cell cycle progression with 
slightly delayed histone mRNA degradation after S-phase ends. Finally, I show that 
stimulated degradation of histone mRNA with hydroxyurea is closely mimicked by the 
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Histone mRNA Metabolism 
Eukaryotic cells replicate their entire genomes in S-phase, and must produce histone 
proteins required to package the newly synthesized DNA into chromatin at the same time.  
The core unit of chromatin is the nucleosome, composed of two copies each of four histone 
proteins, H2a, H2b, H3 and H4.  146 nts of DNA wraps around the nucleosome core, which 
is an octet comprised of a tetramer of H3-H4 and two dimers of H2a-H2b proteins 
(Kornberg, 1977). The H1 protein (about 1 molecule per nucleosome), binds to the DNA 
where it enters and exits the nucleosome and to the linker DNA between nucleosomes to help 
stabilize and maintain shape of the chromatin (Hizume et al., 2005).  
There are two types of histone genes, replication-dependent and replication-
independent. The bulk of the histone proteins are encoded by the replication-dependent 
histone genes, which are active only during S-phase.  These replication-dependent histone 
mRNAs are capped at the 5’ termini, contain a 5’ and 3’ UTR, and have no introns to splice 
out during processing. The 3’ UTR is of note as the replication-dependent histone mRNAs 
are the only known mRNAs in the cell that do not have a polyA tail, but rather end in a 
conserved stemloop structure. This stemloop structure is integral to the unique metabolism 
and regulation of replication-dependent histone mRNA.  
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The replication-independent histone genes are expressed throughout the cell cycle, 
such as variant H3.3 (Wells and Kedes, 1985), or independently of DNA synthesis, like H5 
(Krieg et al., 1982; Molgaard et al., 1980), an histone H1 homologue. H3.3 has been shown 
to replace old replication-dependent H3 histone proteins in differentiated cells over time. It 
also can be incorporated into chromatin independently from DNA replication, replacing the  
existing H3 outside of S-Phase (Ahmad and Henikoff, 2002), to alter expression of specific 
genes. These replication-independent histone genes encode polyadenylated mRNAs, many of 
which are spliced.  They do not have the stem-loop structure in the 3’ UTR of the mRNA, 
which the replication-dependent histone genes require for their metabolism.  
The cell’s method of regulating histone message is primarily post-transcriptional. 
When DNA synthesis ends at the conclusion of S-phase, the cell must ensure that it ceases 
production of the histone proteins, and as a result, has developed a tightly controlled separate 
pathway for regulating histone expression. This highly regulated pathway allows the cell to 
increase histone mRNA levels 35-fold (by increasing transcription and processing) as cells 
enter S-Phase, and then rapidly reduce histone mRNA levels at the conclusion of S-Phase 
(Fig. 1.1). The post-transcriptional regulation end of histone mRNA involves both unique 
cis- and trans- elements. Replication-dependent histone mRNAs are the only metazoan 
mRNAs that do not end in a polyadenylated tail, but rather in a conserved stemloop structure 
in the 3’ UTR. This stemloop is a critical cis element for cell-cycle regulation of histone gene 
expression, participating in processing, transportation, translation and degradation (Harris et 
al., 1991; Mullen and Marzluff, 2008; Sanchez and Marzluff, 2002; Wang et al., 1996). The 
trans-factor that binds the stemloop is the Stemloop Binding Protein (SLBP), whose only 
known binding partner is the conserved histone mRNA stemloop (Brooks et al., 2015; Wang 
3 
 
et al., 1996). SLBP also coordinates the metabolism of histone mRNA, sharing some factors 
with polyadenylated mRNA metabolism, but differing in others. 
Fig. 1.1. Histone mRNA Cell Cycle Regulation. 
Histone mRNA levels dramatically increase as 
cells enter S Phase, and rapidly decrease at 
the end of S-phase. Histone mRNA degradation 
can be activated by treatment with 
hydroxyurea (HU) during S Phase.  
The human histone genes are present in multiple copies in the genome in two large 
clusters, HIST1 on chromosome six and HIST2 located on chromosome one. The HIST1 
cluster encode all five histone proteins: the four core proteins H2A, H2B, H3, and H4, along 
with the linker histone H1. HIST1 contains 55 copies of the histone genes, while HIST2 
contains 11 genes (Marzluff et al., 2002), all encoding the four core histone proteins. These 
localized regions of the genome are each present in a Histone Locus body (HLB) allowing 
efficient transcription and processing of nascent histone mRNAs (Marzluff and Koreski, 
2017; Tatomer et al., 2016). 
 
Histone pre-mRNA processing 
Histone mRNA processing involves both capping the 5’ end and cleavage 
downstream of the stem loop shortly after it is transcribed, as the histone genes do not 
contain introns, and the stop codon is very close (~50nt) to the stemloop. Downstream of the 
stemloop structure, there is a cis-element, the Histone Downstream Element (HDE) which 
binds the 5' end of U7 snRNA in the U7 snRNP.  A ring of 7 proteins (Lsm10, Lsm11, and 
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five Sm proteins) form around the U7 RNA and then this ring will bind the scaffolding 
protein FLASH and other proteins including the endonuclease CPSF73 that catalyzes the 
cleavage (Dominski et al., 2005; Skrajna et al., 2017, 2018).   SLBP binds the stemloop and 
stabilizes the binding of the U7 snRNP binds to the HDE U7 antisense sequence just 
downstream of the stemloop.   CPSF73 cleaves five nucleotides past the stemloop, generating 
a mature, capped, histone mRNA molecule (Fig. 1.2). 
After processing, the stemloop  remains bound to SLBP and  binds the 3’ to 5’ 
histone exonuclease (3’hExo) which contacts the opposite side of the stemloop from SLBP 
without directly touching SLBP (Tan et al., 2013). This 3’ exonuclease then degrades 2nt 
further from the 3’ termini before being limited by SLBP on the other side of the stemloop. 
This additional trimming produces a 
final cytoplasmic histone mRNA 
molecule ending in a stemloop with 
a 3nt tail (Dominski et al., 2003; 
Yang et al., 2006).  
Fig. 1.2. 3’ Processing of Histone 
mRNA. Nascent transcript is cleaved 
5nt downstream of stemloop and 
trimmed to ~3nt past the stemloop 
by 3’hExo.  
 The mature transcript is exported from the nucleus to the cytoplasm for translation. 
Similar to polyadenylated transcripts, histone mRNAs are circularized for translation. SLBP, 
the trans-factor bound to the stem loop, has been shown to be required for translation 
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(Sanchez and Marzluff, 2002; Whitfield et al., 2004). In polyadenylated transcripts, the 
polyadenosine binding protein on the 3’ termini bind to EIF4G associated with the 5’ cap to 
circularize for translation (Wells et al., 1998). However, SLBP does not directly associate 
with EIF4G bound to the 5’ end of histone mRNA, but rather with SLIP1, which also binds 
to EIF4G and EIF3g to complete the circle and begin translation (Fig. 1.3)(Cakmakci et al., 
2008; Von Moeller et al., 2013). 
 
Histone mRNA Regulation 
 All replication-dependent histone mRNAs are cell-cycle regulated to ensure the 
proper levels of histone protein can be produced each cell cycle dependent on expression and 
degradation regulation. This regulation is controlled by four distinct steps: rate of 
transcription, rate of pre-mRNA processing, mRNA half-life changes, and rate of degradation 
of excess histone protein. These steps all work together to ensure that there is enough histone  
replication is occurring and no excess during the rest of the cell cycle. Shortly before S Phase 
begins, expression of histone mRNA sharply increases approximately 35-fold and remains 
there for the duration of DNA replication. By changing the histone promoter to a constitutive 
promoter, post transcriptional regulation has been shown to account for about 10-fold of the 
35-fold change of cell-cycle dependent histone mRNA regulation in Chinese hamster cells, 
implicating the 3’ terminus of histone mRNA as a key regulator  (Harris et al., 1991). In 
coordination, SLBP protein levels increase as cells enter S-phase allowing efficient pre-
mRNA processing (Whitfield et al, 2002).  
At the end of S Phase, histone mRNA levels rapidly drop back down to basal levels in 
G2, before cells enter mitosis. At the conclusion of S Phase, SLBP is also degraded, to  
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Fig. 1.3. Life of the 
Histone mRNA. 
Metabolism of the 
histone mRNA sees it 
processed in the 
nucleus and cleaved, 
exported to the 
cytoplasm, trimmed, 
and then circularized 
for translation before 
being degraded. SLBP 
is a key trans-factor 
through the whole 
process. 
prevent further histone pre-mRNA processing.  However, while SLBP is required for many 
processes of histone mRNA metabolism, its expression is not directly tied to histone mRNA 
during S Phase, but rather it is regulated by cell cycle signals. When DNA synthesis is 
inhibited in S-phase resulting in histone mRNA degradation, SLBP protein expression is 
unaffected (Whitfield et al., 2004). SLBP has been shown to be degraded upon activation of 
cyclin A-CDK1 at the end of S-Phase (Koseoglu et al., 2008). However, histone mRNA must 
be degraded for SLBP to be degraded, highlighting the delicate balance between SLBP and 





 The half-life of an mRNA is as important in determining steady-state levels of an 
mRNA as the rate of transcription.  Excluding the histone mRNAs, all eukaryotic cellular 
mRNAs end in a 3’ polyadenylated tail. This polyA tail plays a role not only in translation 
and stabilization of the message, but also in degradation of the mRNA. The polyA tail is 
normally bound to polyA Binding Proteins (PABP), which protect it from the degradation 
machinery of the cell. However, the initial step in mRNA degradation is generally 
deadenylation; the polyA tail is deadenylated down to a short number of adenosines 
primarily by the CCR4/NOT complex, which degrades the polyA tail removing the polyA 
bind protein (Webster et al., 2018). This deadenylated tail can then recruit the Lsm1-7 ring 
that initiates decapping by binding to decapping activator Pat1 (Tharun et al., 2000). 
Dcp1/Dcp2 can then decap the mRNA, and allow 5’ to 3’ degradation by Xrn1 exonuclease 
(Hsu and Stevens, 1993; Tharun and Parker, 2001). Alternatively, the deadenylated RNA 
may be retained in the cell and potentially readenylated and then translated again This 
decapping and 5’ to 3’ degradation has been demonstrated extensively in yeast, but not as 
robustly in higher organisms (Coller and Parker, 2005). It is possible that 3’ to 5’ degradation 
is as important as 5’ to 3’ degradation or even the more favored form of degradation in 
higher eukaryotes. 
 
Histone mRNA degradation  
Histone mRNAs share some similarities with polyA mRNAs regarding degradation, 
but differ in others. When DNA synthesis is inhibited in S-phase cells, it activates histone 
mRNA degradation.  Histone mRNA is also rapidly degraded at the end of S-phase in order 
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to prevent continued histone protein synthesis once DNA synthesis is completed. In order to 
accomplish this regulation, the stem-loop is again a key factor in metabolism (Harris et al., 
1991; Pandey and Marzluff, 1987). Early studies by Jeff Ross and coworkers showed that 
histone mRNA degradation could be initiated 3’ to 5’ and that degradation required the 
stemloop at the 3’ end of the histone mRNA be located close to the stop codon (Ross and 
Kobs, 1986; Ross et al., 1986).  Translation of the histone mRNA is also required for 
degradation (Graves et al., 1987; Kaygun and Marzluff, 2005a). In addition, our lab 
identified Upf1, an RNA helicase involved in Nonsense Mediated Decay (NMD) as a factor 
required for histone mRNA degradation. UPF1 has also been shown to be recruited to the 
stemloop and required for histone mRNA degradation (Kaygun and Marzluff, 2005b; Meaux 
et al., 2018).  
To identify degradation intermediates in histone mRNA degradation, we turned to 
sequencing. Tom Mullen circularized cellular RNAs after treating cells with DNA synthesis 
inhibited, and used inverse-PCR to identify decapped histone mRNAs. He sequenced them to 
identify the termini of degradation intermediates.  As part of this analysis he also discovered 
that the cytoplasmic histone mRNA’s ended 3nt past the stemloop, rather than 5nt, 
implicating 3’hExo in the trimming process. In addition, using RNAi, Mullen found that 
Lsm1 was required for histone mRNA degradation and is associated with the histone mRNA 
only during degradation, potentially by binding the oligoU tail present in degradation 
intermediates (Mullen and Marzluff, 2008). This implies that Lsm1-7 bind during 
degradation, which might then recruit the decapping complex and/or the exosome complex 
for 3’ to 5’ degradation. His RNAi results also indicated what the exosome was important for 
histone mRNA degradation, while the 5’ to 3’ pathway was less important. 
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Shawn Lyons continued to study the role of the Lsm1-7 complex in relation to histone 
mRNA degradation. Lyons found that the C-terminal tail of Lsm4 bound to SLBP and 
3’hExo, and was also required for histone mRNA degradation (Lyons et al., 2014). In order 
to better study degradation intermediates at the 3’ termini of histone mRNA, which seemed 
to be an indicator of ongoing degradation, Michael Slevin, Stacie Meaux and Joshua Welch 
developed a deep sequencing technique to identify the 3’ end of degradation intermediates 
including any non-templated tails added to histone mRNA with a single nucleotide 
specificity. Slevin and Welch developed the EnD-Seq/AppEnd workflow to prepare histone 
mRNA libraries with histone specific primers and a novel 3’ ligated sequence to preserve the 
3’ termini and the bioinformatics software to analyze the data (Welch et al., 2015). The work 
I present in the second chapter of this dissertation will continue to expand on this technique. 
They initially focused on longer oligoU tails (>2 nts) present on the majority of histone 
mRNAs present on degradation intermediates which were not found on histone mRNAs 
stable during S-phase.  They identified intermediates with these longer tails present in 
degradation intermediates such as the stemloop and near the stop codon (Slevin et al., 2014).  
With the final development of the END-Seq software, we showed that the majority of 
histone 3’ termini in S-phase cells actually end in one or two nontemplated uridines to 
maintain the length of 3 nucleotides past the stemloop.  The 3’ end of histone mRNAs in S-
phase do not always end in the templated ACC 3nt after the stemloop, but occasionally end 
in ACU or AUU with one  or two non-canonical uridines to maintain 3nt past the stemloop 
(Lackey et al., 2016; Welch et al., 2015).  Using RNAi another graduate student in the lab, 
Patrick Lackey, got evidence suggesting that TUT7, and not TUT4, is the TUTase 
responsible for adding the uridines, and works together with 3’hExo to regulate histone 
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mRNA 3’ termini (Lackey et al., 2016). Lackey’s work with siRNA knock downs of TUT7 
and 3’hExo helped form the basis of my work making stable CRISPR knock outs of TUT7 
and 3’hExo, along with characterizing the cell-cycle regulation of histone mRNA 
degradation using EnD-Seq libraries, as covered in chapter three of this dissertation.  
While the histone mRNA is being maintained at this length, it will remain actively 
translated, and bound to SLBP. While the histone mRNA is being translated, it is still bound 
to SLBP and 3’hExo (Brooks et al., 2015). The 3’ terminus is still left open for degradation 
and subsequently further uridylation. The 3’ termini are in a form of tug of war where TUT7 
uridylates the end of the molecule to slowly stunt the degradation further into the stemloop 
by 3’hExo. Once 3’hExo removes the nt, TUT7 can add a uridine to replace the length. 
TUT7 exhibits monouridylation activity at this phase, adding single uridine residues at a 
time. This maintainence of the length of the 3’ termini allows the histone mRNA to maintain 
a longer half-life, and continue being translated efficiently.  
Pathway of Histone mRNA Degradation  
 Histone mRNA degradation is initiated very rapidly (<5-10 minutes) after inhibition 
of DNA replication (Graves and Marzluff, 1984). The mRNA must continue being translated 
to be degraded. The molecular event on the histone mRNP that triggers histone mRNA 
degradation is not known. 3’hExo is essential for degradation (Hoefig et al., 2013). The 
initial change in histone mRNA structure is degradation by 3’hExo as it begins to degrade 
further into the histone mRNA, up into the stemloop (Slevin et al., 2014). This is the first 
degradation intermediate that accumulates. When degradation begins into the stemloop, 
histone mRNAs are uridylated with  longer oligouridine tails (Slevin et al., 2014). These long 
oligouridine tails can bind the LSM 1-7 complex to the 3’ termini of histone mRNA (Lyons 
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et al., 2014), which can then ultimately recruit the 3’ to 5’ exosome complex (Chowdhury et 
al., 2007; Song and Kiledjian, 2007). Very few degradation intermediates are found between 
the loop in the stem loop and the region between the stemloop and the terminating ribosome.  
This likely results from removal of SLBP and Upf1 from the histone mRNA, allowing the 
exosome to processively degrade histone mRNA until it degrades close to the stop codon.  
The second degradation intermediate observed is 17nt downstream of the stop codon, and 
many of the intermediates are also uridylated although the U-tails are not as long as in the 
stem.  These intermediates are likely due to a stalled ribosome on the stop codon blocking the 
exosome’s progression (Guydosh and Green, 2014; Wolin and Walter, 1988). Further 
degradation intermediates appear through the coding region, as the exosome continues to 
encounter more bound ribosomal complexes (Fig. 1.4).   All these intermediates are 
associated with polyribosomes (Slevin et al). Many histone mRNA molecules being degraded 
3’ to 5’ have been shown to still retain their 5’ caps (Slevin et al., 2014; Su et al., 2013), 
despite the fact that oligoU tails on RNAs together with Lsm1-7 can stimulate decapping 
(Song and Kiledjian, 2007).  Histone mRNAs have also been found to be simultaneously 
decapped and degraded 3’ to 5’ (Mullen and Marzluff, 2008). This suggests that most 
decapping occurs as a later step in the degradation of histone mRNA. 
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Fig. 1.4. 3’ stabilization by 
addition of nontemplated uridines 
to maintain length past the 
stemloop. Degradation involves 
longer uridiylation and results in 
two main degradation 
intermediates, the stemloop 
(paused until SLBP is removed) 
and the stop codon (paused by 
stalled ribosome). 
 
URIDYLATION AND ADENYLATION 
 Most mature mRNAs have non-templated nucleotides added on the 3’ termini. Most 
mRNAs have a polyA tail that stretches up to 200 adenosines in mammals, added by polyA 
polymerase as part of cleavage/polyadenylation.  The polyA tail binds polyA Binding Protein 
(PABP) that bind to the whole length of the tail and protects it from deadenylation. The 
bound PABP also associates with EIF4E and EIF4G, which circularizes the mRNA for 
translation (Wells et al., 1998). In addition to stabilizing the message and recruiting 
circularization factors, the polyA tail also serves to signal degradation of the mRNA when it 
is shortened to about 10 nts.  It can no longer bind PABP, but does bind Lsm1-7, which will 






Fig 1.5. TENT Family of proteins. Adapted from Warkocki et al. 2018. 
Terminal Nucleotidyl Transferases 
 In addition to polyA polymerase, there is a set of TErminal Nucleotidyl Transferases 
(TENTs) that can primarily add either adenosine or uridines to RNAs.  These have a non-
canonical polyA polymerase domain (PAPD). The nomenclature for these has been changed 
in the past year, since they were named as they were discovered. Figure 5 shows the human 
(mammalian) TENTs, together with their previous names.  Three of the TENTs: TENT1, 
TENT3A and TENT3B are uridyl transferases, while the others are adenyl transferases. 
Unlike polyA polymerase, which adds the long tails to mRNAs, that nucleotide specificity is 
not absolute and other nts are observed in the A or U tails added by the TENTs.    
For defective RNAs in the nucleus, the TRAMP complex, including the TENT Trf4, 
adds a short adenosine tail (4-5nt) to the 3’ termini of the RNA, before losing its affinity for 
ATP (Wlotzka et al., 2011). This short A tails helps recruit Mtr4, a TRAMP component, 
helicase activity to initiate degradation by the RNA exosome (Jia et al., 2011).  
Another cellular pathway that TENTs are involved in is apoptosis. Uridylation, 
particularly by TUT7 and TUT4, have been implicated in as the mechanism that triggers 
global degradation of mRNAs. The mRNAs are uridylated by TUTases, and then targeted by 
DIS3L2, a 3’ to 5’ exonuclease, for degradation. When TUT4, TUT7, or DIS3L2 are 
knocked down, the apoptotic pathway is slowed (Thomas et al., 2015). 
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 There are many other RNA molecules that are targeted for adenylation and 
uridylation.  miRNAs and pre-miRNAs often have either U-tails or A-tails.  These can 
participate in miRNA biogenesis and stabilization as well as miRNA and pre-miRNA 
degradation.   A general mechanism for degrading structural RNAs, snRNAs, tRNAs, 
snoRNAs, and other structural and lncRNAs, involves uridylation, followed by degradation 
by the processive 3’ to 5’ exonuclease, DIS3L2.  The unifying feature of the 
DIS3L2/Uridylation targets is that they are often misprocessed or the RNA has formed stable 
incorrect secondary structures. This suggests that the DIS3L2/Uridylation pathway serves to 
check and remove misprocessed RNAs where structure is key to function (Ustianenko et al., 
2016). Since this is a new field, only a few roles of uridylation are known, and less is known 
about the cofactors/cis-elements that are required. 
 
TENTS and Uridylation 
The enzymes responsible for uridylation are of the TENTs/TUTase family of proteins 
(Terminal Nucleotidyl Transferases/Terminal Uridyl Transferases). These enzymes were 
initially termed non-canonical polyA polymerases since the active site of the TENTS is a 
PABPD domain. These enzymes all have a nucleotidyl transferase domain from DNA 
polymerase β, along with a PAP associated domain.  In the TUTases, the nucleotidyl 
transferase domain prefers to bind and add uridines (Martin and Keller, 2007).  
 In addition to the PAPD and PAP-associated domain, some proteins in the TENT 
family contain different zinc finger domains, which are theorized to assist in binding to 
unique RNA substrates (Aravind and Koonin, 1999). However, this is where the similarities 
among the TENTs end. Most of the regions between catalytic domains are not conserved 
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from TENT to TENT, and are often identified with DISOPRED as disordered RNA binding 
regions, suggesting each TENT has a specific role to play within the cell, and that 
evolutionary selection occurred long ago (Jones and Cozzetto, 2015; Scheer et al., 2016; 
Warkocki et al., 2018a).  
 There are specific TENT proteins in different parts of the cell, both inside the 
nucleus, the cytoplasm, or the mitochondria (Lubas et al., 2011; Nagaike et al., 2005). They 
also vary drastically in size. Some of the largest TENTS, TUT7 and TUT4, approach 1600 
amino acids, while some of the smaller TENTS are only ~400 amino acids long (Warkocki et 
al., 2018a). Warcocki et al. classified TENTS into three main groups based off function and 
organization: polyadenylase TENTS (those that add primarily adenosine residues), TUT1 
(which may either polyadenylate or oliguridylate), and the TUT4/7 group (oligo- and 
monouridylation) (Fig. 1.5).  
Our lab has previously analyzed several different human cell transcriptome libraries 
and found that at the RNA level,  TUT4 and TUT7 are similar in expression to the other, with 
TUT7 being present 1.3 times higher than TUT4 (Lackey et al., 2016). Looking at GTEx 
data, which is transcriptome expression across tens of human tissue samples, I also found that 
TUT7 and TUT4 are similar in expression. TUT7 and TUT4 have a nearly 1:1 ratio in most 
tissues, with a lowest ratio of 0.2 in the Cerebellum, and a highest ratio of 5.6-fold expression 
of TUT7 in whole blood. There is a large amount of sequencing data from tumors.  I looked 
at TUT4 and TUT7 in the Cancer Cell Line Encyclopedia) we found that TUT7 (Average 
19TPM) and TUT4 (Average 11TPM) are again similarly expressed, by a factor of 2.1 fold 
higher expression of TUT7 (low of 0.8 in NCI-H1355 and a high of 7 fold higher TUT7 
expression in HCC2935, both lung cell lines). However, in relation to other proteins, the 
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amount of expression of the TENTs is unknown. When compared to a PolyA Binding 
Protein, PABPC4, all TUT4 and TUT7 had much lower expression in comparison (how 
much >10-fold). When TUT7 is compared with 3’hExo transcript expression, in both GTEx 
data and CCLE data, I found a similar expression with a TUT7:3’hExo ratio of 1.3 in CCLE 
data and 2.6-fold higher TUT7 expression in GTEx data.   
 TENTS, including cytoplasmic uridyl transferases, are found in all metazoans and 
plants.  There are polyadenylase TENTS in the yeast S.cerevisiae, but no cytoplasmic uridyl 
transferases, but there is a cytoplasmic uridyl transferase in S. pombe, which has been 
implicated in mRNA stability (ref. Rissland and Norbury).  
 
Polyadenylase TENTs 
 One of the largest categories of TENTS includes those that are able to either 
polyadenylate or oligoadenylating substrates, occasionally incorporating other nucleotides, 
such as guanines, into the nontemplated 3’ tail. Members of this group include the 
cytoplasmic polyadenylase GLD2/TUT2/TENT2, and mitochondrial polyA polymerase and 
the oligoadenylases, TRF4/TENT4A, and GLD4/TUT3/TENT4B. All of these enzymes share 
the same catalytic motif of a nucleotidyl transferase domain adjacent to a PAP-associated 
domain. TRF4 (TENT4A) contains two splicing isoforms in humans, a short and long form. 
The short form is insufficient to polyadenylate RNAs, as it is missing its N-terminal region, 
but still contains the nucleotidyl transferase domain (Ogami et al., 2013). This N-terminal 
region is also vital to the localization of the long form to the nucleus, suggesting that the non-
catalytic regions of the TENTs are important for target regulation, localization, and binding 





 TENT1/TUT1 is of particular interest in that it has some unique protein domains, but 
like TUT7 and TUT4, will perform oligouridylation. TUT1 is primarily nucleolar, and is 
expressed in all human tissues (Pinto et al., 2014; Trippe et al., 2006; Uhlén et al., 2015). It 
contains an additional Proline Rich Region (PRR) and Kinase Associated (KA-1) domain, 
differentiating it from TUT4 and TUT7 (Warkocki et al., 2018a; Yamashita et al., 2017). A 
major role for TUT1 is in U6 snRNA maturation. U6 snRNA transcripts have a four uridine 
tail on its 3’ termini, and post-transcriptional modification adds one uridine via TUT1, along 
with a 2’-3’ cyclic phosphate to complete maturation and protect it from the uridylation 
degradation pathways in yeast (Cid1 topological homologue) (Didychuk et al., 2017; Lund 
and Dahlberg, 1992; Trippe et al., 2003; Yamashita et al., 2017). 
 
TENT 2  
 TENT2, also known as GLD2 or PAPD4, has been primarily implicated in the 
cytoplasm. It has been shown, mostly in non-mammals, to adenylate some cytoplasmic 
mRNA polyA tails and enhance translation (Wang et al., 2002). As mentioned above, it’s 
also been implicated in memory formation by association with Pumilio and CPEB1 (Rouhana 
et al., 2005). Other roles for TENT2 include monouridylation of the liver-specific miRNA-






TENT3A and 3B  
 TENT3A and TENT3B are also referred to as TUT4 and TUT7 respectively. These 
TUTases are two of the longest TENTs and have been implicated in similar pathways. TUT7 
in particular is the enzyme that adds non-templated uridines to the 3’ termini of histone 
mRNA. These enzymes are discussed in greater detail below. 
 
TENT4A and B 
 Previous work in the lab had focused heavily on TUT3/TENT4B’s role in regulating 
histone mRNA, including demonstrating TUT3 interacts with SLBP, but fails to uridylate the 
histone mRNA (Lackey, 2016). TENT4B is also worth noting as both TENT4B and 
TENT4A/TRF4 are both capable of adding in guanines while polyadenylating (Lim et al., 
2018).  This demonstrates that it is not necessarily different isoforms of the protein that can 
add different nucleotides, but the same protein is able to change which nucleotides are added, 
likely depending on substrate and cofactors present. TENT4B has also been implicated in 
several different pathways, including oligouridylation of rRNAs, tRNAs, and histone mRNA 
(Rammelt et al., 2011).   
 
TENT5 and TENT6 
 TENT5A-D is currently comprised of four relatively newly discovered proteins, 
FAM46A, B, C and D. Most of what is known about these TENTs comes from in silico 
discovery and domain analysis (Kuchta et al., 2009). TENT6/TUT6/mtPAP is the only 
known TENT localized to the mitochondria, and functions as a polyA polymerase within the 
mitochondria (Tomecki et al., 2004). It is also capable of utilizing all four nucleotides in it’s 
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catalytic domain (Bai et al., 2011). For the newly discovered TENT5A-D proteins, more 
research and characterization can highlight their unknown roles in mammals and other higher 
organisms. 
 
Fig. 1.6 Domain Organization of TUT7 and TUT4. 
 
Roles of the Two Major Uridyltransfeases: TUT7/TENT3B and TUT4/TENT3A 
 TUT7 and TUT4 are of particular interest as they have similar structures and 
uridylate many of the RNAs in the cell, and have been implicated in multiple pathways of 
regulation (Lackey et al., 2016; Thornton et al., 2014; Warkocki et al., 2018b).  TUT7 and 
TUT4 each have two highly conserved catalytic domains, one active domain towards the C-
terminal and one inactive domain towards the N-terminal (Fig. 1.6). Both TUT7 and TUT4 
catalytic dead domain replicates are missing key catalytic aspartates in the Nucleotidyl 
Transferase Domain. The regions flanking these catalytic domains are not conserved between 
the two TUTases and are intrinsically disordered.  These flanking regions are extensive (up 
to 400+ aa long) considering TUT4 and TUT7 are both 1500+ amino acids long, while the 
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catalytic regions typically are only a fraction of the entire peptide, ~300 aa (Scheer et al., 
2016). Both TUT7 and TUT4 will bind uridines and transfer uridines rather than adenosines 
in vivo. TUT4 and TUT7 have generally been found to be able to uridylate the same RNAs in 
vitro if presented with the same substrate RNA molecule (Faehnle et al., 2017; Lim et al., 
2014). 
 In the best studied case, either TUT7, or its homolog TUT4, have been shown to be 
able to regulate let-7 miRNA (Faehnle et al., 2017; Kim et al., 2015) production, by 
uridylating let-7 pre-miRNA. Monouridylation of let-7 pre-miRNA results in production of 
mature let-7.  In the presence of lin-28, which binds the let-7 pre-miRNA, the TUTase 
oligouridylates the pre-miRNA resulting in its degradation and downregulating let-7 miRNA. 
Previous work in our lab has suggested that TUT7, and not TUT4, is the TENT that 
uridylates histone mRNA  (Lackey et al., 2016). 
The monouridylation of histone mRNA serves to maintain the required 3 nt past the 
stemloop and protect it from degradation, whereas the oligouridylation of pre-let-7 in 
differentiated tissues, inhibits full maturation into functional let-7 miRNA (Heo et al., 2012). 
The oligouridylation of histone mRNA by TUT7 is prevalent in degradation intermediates of 
3’ to 5’ mediated decay, where the longer uridine tails may be recruiting the exosome. When 
pre-let-7 is monouridylated by TUT4/TUT7, this uridine signals processing the pre-miRNA 
to its matured form.  
 TUT4 and TUT7 both have also been implicated on uridylating short, deadenylated 
polyA transcripts (Lim et al., 2014). These transcripts normally possess no longer than 10-20 
nt adenosine tails, and about 10% of them are then tailed with 1-3 uridines, suggesting that 
uridines play a role in stabilizing transcripts after deadenylation occurs.       
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CURRENT METHODS TO STUDY URIDYLATION 
In Vitro Assays 
 Current methods exist to study uridylation, with one of the oldest being in vitro 
assays done outside of the multicellular organism. This could be done in a test tube with 
purified enzymes from bacterial expression system, or endogenous proteins 
immunoprecipitated from cell extracts. The latter is beneficial, as you may retain necessary 
cofactors. These proteins can then be incubated with a target RNA molecule and radiolabeled 
uridine that can be visualized when the RNA is run out on a gel and exposed to film or 
phosphorescent screens. 
Identifying uridylation events in vivo is more difficult, since it requires identifying the 3’ end 
of the mRNA precisely.  One straight-forward process of identifying uridylation events of an 
RNA is with Sanger sequencing. The RNA of interest would be reverse transcribed with an 
oligoU primer and then amplified with PCR. The PCR would then be cloned into plasmids to 
identify each novel molecule’s 3’ termini. However, the danger of this method is that there is 
no accurate way to confirm that all molecules are amplified equally with such an unspecific 
primer, or properly identifying small populations if uridylation is a rare event or 
monouridylated. Additionally, Sanger Sequencing long stretches of the same nucleotide, 
which may be required for some of the polyA TENTs samples, is prone to nucleotide 
skipping either during PCR amplification or during the sequencing process, although this 
method will be very accurate with oligouridylation. Possible methods to sanger sequence 
uridine tails is to 1) circularize the RNA, 2) prime the cDNA with a short oligo dA primer 
(similar to RACE-seq), or 3) ligate primer to 3’ termini and reverse transcribe off that primer. 
The struggle with any of these is the sheer amount of sequencing required. One clone can be 
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sequenced at a time, which is just very time intensive. In addition, specific primers would 
have to be used to amplify, making it more difficult to apply this broadly.  
RACE seq was developed by Frohman, Dush, and Martin in 1988 using novel cDNA 
cloning techniques at the time. The approach to study the 3’ termini was to reverse transcribe 
mRNA, PCR amplify the cDNA using a known gene sequence, and cloning into a plasmid 
for transfection and subsequent colony sequencing via Sanger Sequencing (Frohman et al., 
1988). This gave the ability to amplify rarer mRNA transcripts, and retain post-
transcriptional modifications of the RNA molecule, such as alternative splicing and non-
templated tails. The limitations of this technique, however, are the number of clones one can 
feasibly sequence, as well as the fact that cDNA amplification and subsequent PCR may not 
evenly amplify subpopulations of RNAs, and rare post-transcriptional events may not be 
visible without extensive screening. These rare events can be observed with the scope of 
deep sequencing providing millions of reads per library, rather than however many colonies 
can be picked and sequenced with RACE seq. 
 Another in vitro method to study uridylation is an S1 Protection Assay. The concept 
behind this assay is that the S1 endonuclease cleaves and degrades any ssRNA molecule. 
Using multiple probes for different forms of your RNA of interest, for example a skipped 
exon, pre-mRNA with introns, or an oligoU tail, you can hybridize these radiolabeled probes 
to your RNA, creating S1 resistant dsRNA/DNA hybrid. The limitations of this approach are 
that comprehensive probes must be used to identify RNA populations, and any non-
templated tails may be improperly accounted for, making it nearly impossible except in 





 Upon the advent of deep sequencing, the potential to identify modified RNAs of all 
types much more feasible, even if the modification was a rare event.  There are several 
methods to develop RNA based libraries for studying uridylation. Rapid Amplification of 
cDNA Ends, or RACE, sequencing was one of the earlier methods for sequencing RNA 
(Frohman et al., 1988). While not deep sequencing, it’s worth noting, as it is the basis of 
many RNA sequencing techniques used today, and was used to identify early non-templated 
uridine tails of histone mRNA and other deadenylated mRNAs (Couttet et al., 1997; Mullen 
and Marzluff, 2008).  
 Circle Sequencing is a deep sequencing method originally developed to identify 
mutations in ssDNA strands, but can be adapted for RNA as well (Couttet et al., 1997). One 
limitation is the circularized mRNAs will have to be decapped somehow. The principle 
behind Circle Seq is that the cDNA is circularized, and then rolling circle PCR makes long 
amplicons of repeat regions that are turned into a deep sequencing library. Each PCR product 
sequenced can then be deconvoluted to identify actual mutations/nontemplated tails versus 
PCR generated errors. The primary limitation of this method is that sequencing long 
polyadenosine tail regions is still highly prone to errors, so cDNA synthesis must be properly 
directed to maintain a reasonable size.  
 A popular method for identifying non-templated 3’ tails on RNAs is TAIL-seq, 
developed by Narry Kim’s lab (Chang et al., 2014). Like many other RNA sequencing 
techniques, TAIL-seq does require RNA selection, such as rRNA depletion. The RNA is 
ligated to a known 3’ adapter sequence and partially degraded with RNase T1 to fragment the 
RNA molecule. The ligated RNAs are then pulled down with streptavidin and purified via a 
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gel to remove smaller short ncRNAs that may contaminate the library. From this purified 
pool, the RNA is reverse transcribed and amplified using library adapters for deep 
sequencing to get a close look at what is happening on the 3’ termini. The TAIL-seq method 
gives single nucleotide resolution on the 3’ termini due to the ligation of the known linker 
sequence to the post-transcriptionally modified RNA molecules as they exist in the cell upon 
harvest. It has been used to identify A/G mixing in polyadenosine tails in mRNA as well 
(Lim et al., 2018). However, one of the limitations for TAIL-seq is the extensive handling 
and purifying of the RNA samples before reverse transcribing into more stable cDNA. 
Initially, the RNA is treated with an RNase, which is difficult to control how much is actually 
degraded. This, along with all the other processing steps and filtration, lead to extensive 
batch effects from library to library. The other requirement is that the libraries must be run on 
a Hi-Seq or similar deep sequencing machine.  
 The EnD-Seq (ExoNuclease Degradation Sequencing) and AppEnD (Application for 
mapping EnD-Seq data) workflow provide the basis for all deep sequencing experiments 
performed in this thesis, and provide insight into the 3’ terminus of RNA molecules without 
greatly perturbing them during library generation (Welch et al., 2015). The library 
preparation is similar to the RACE-seq basis presented earlier, where RNA is reverse 
transcribed into cDNA and then amplified via PCR for deep sequencing by adding deep 
sequencing adapters during amplification. One of the key features of EnD-Seq library 
preparation is the known 3’ adapter sequence that is ligated to the 3’ terminus of every RNA 
molecule in the cell, as is the case with TAIL-Seq. A special ligase is used to ligate the 
“linker” sequence in the absence of ATP, to prevent cyclization or concatamerization and 
increase efficency. The linear RNA can then be reverse transcribed using the linker sequence 
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as a priming site, while leaving any non-templated 3’ nucleotides or degradation/processing 
events intact. This gives sequencing runs single nucleotide resolution of the 3’ termini of 
RNA molecules of interest. After cDNA is generated, gene specific primers, in our case 
histone specific primers, can be used to amplify only the genes of interest, without having to 
perform ribodepletion, and allowing us to generate libraries and specific sizes without gel 
filtration or RNase treatment. EnD-Seq allows the depth required for specific genes to 
identify rare post-transcriptional modifications or transient degradation intermediates. The 
App-EnD workflow is the computational approach to EnD-Seq analysis, where the 
sequencing data is aligned to the known genome to identify reads with the proper gene of 
interest. Any nucleotides not aligned are soft-clipped, and re-aligned from the linker 
sequence, demonstrating these nucleotides are post-transcriptionally added and are not 
sequencing errors. App-EnD then appends the sequence to show which canonical nucleotide 
the RNA molecule stopped at and how many non-canonical tail nucleotides were added at 
that position.  
 
CRISPR Cas9 Gene Editing 
 The development of CRISPR Cas9 gene editing has revolutionized study of gene 
hfunction, particularly in multicellular organisms.  The elegance of CRISPR Cas9 gene 
editing is that it is a permanent change to either an in vivo (whole animal) or in vitro (cell 
culture) system. For studying uridylation, there are two main choices for gene editing, you 
can target the genomic sequence of the RNA substrate, or you can target the genomic 
sequence of the TENT of interest, or of other proteins or RNAs involved in the uridylation 
complex. For either choice, there are still multiple ways to probe the system. One of the most 
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straight-forward is to use CRISPR Cas9 to introduce an insertion/deletion mutant (indel) that 
induces a frameshift mutation to create and early stop codon in the TENT protein, knocking 
it out and demonstrating what role the TENT had within the system. 
 The other method would be to use homologous recombination repair to introduce a 
tag of some kind to your RNA substrate or TENT of interest. By providing a template strand 
with the desired tag or point mutation (e.g. to remove a potential binding site for the RNA 
substrate or catalytic site of the TENT), CRISPR Cas9 can induce a repair mechanism that 
will incorporate the template via homologous recombination. This is also useful when 
working on RNA substrates or TENTS that are essential genes, where a general knock out 
would be lethal to the organism. 
 
SUMMARY 
Histone mRNA production is amplified at the beginning of S-phase and the molecules 
themselves are stabilized to allow for translation of new histone complexes. At the end of S-
phase, the histone mRNAs are rapidly degraded and return to the low levels present in G1. The 
3’ terminal stemloop (and SLBP) mediates this degradation pathway, along with every other 
major metabolism step for the histone mRNA, including processing, transportation, 
circularization and translation.  
Unlike other mRNAs that are polyadenylated, the stemloop and SLBP on histone 
mRNAs provide an alternative pathway for mRNA metabolism. The Marzluff lab has worked 
for decades to deconvolute the metabolism pathway of histone mRNA, and have developed a 
novel deep sequencing approach (EnD-Seq) to identifying the 3’ terminus of histone mRNA 
to grant better insight into stabilized and degrading histone mRNA molecules. Previous work 
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by the lab has identified that a stemloop-bound exonuclease, 3’hExo, and a uridyl transferase 
work together to add short or oligo uridine tails to either stabilize or promote degradation of 
the histone mRNA.  
In the following chapter, I focus on the EnD-seq library preparation. I worked to 
improve yields of the required linker sequence, along with improving ligation efficiency of the 
linker to RNAs. I also sought to address the lack of clearly defined protocols for generating 
EnD-Seq libraries, which does not utilize any library preparation kits on the market. Chapter 
Three focuses on my work on the stabilization and degradation of histone mRNA, which 
utilizes the library methods improved in Chapter Two. I generated CRISPR single knockout 
cell lines for TUT7 and 3’hExo to identify their roles in histone mRNA metabolism throughout 
the cell cycle. My work has produced clear evidence that TUT7 and 3’hExo both function to 
stabilize histone mRNA during S-phase.  3’hExo is required for degradation initiation, and 
TUT7 is essential for efficient degradation. In the fourth chapter I discuss the conclusions and 
suggested models for stabilization and degradation of histone mRNA, along with the novel cell 
cycle phenotypes identified in the histone mRNA. I also address possible future directions to 
take the EnD-Seq libraries for more global transcriptome or other small RNAs sequencing of 
the knock-out cells I generated. 
 The knock out cell lines generated and improved EnD-Seq protocol has 
answered many questions knock downs and traditional sequencing could not, but the cells I 
generated have much more information to give as technology in sequencing and cell analysis 







DETERMINING DEGRADATION INTERMEDIATES AND THE PATHWAY OF 3’ TO 
5’ DEGRADATION OF HISTONE mRNA AND HIGH-THROUGHPUT SEQUENCING 
 
INTRODUCTION 
The final step in metabolism of an RNA molecule is degradation of the RNA.  Since 
the steady-state level of an RNA is a balance of the rate of synthesis and the rate of 
degradation, the half-life of an RNA is as important as its rate of synthesis in determining the 
level of any RNA molecule in the cell.  Messenger RNAs have a wide range of half-lives in 
eukaryotes, ranging from a few minutes to many hours, or even days.  Not only does the half-
life of an mRNA contribute to its overall level in the cell, but if the cell needs to rapidly 
reduce the level of an mRNA, the only way to do that is to rapidly degrade the mRNA. Most 
mRNAs are protected from degradation by specialized elements at the ends of the RNA; a 
cap at the 5’ end of the mRNA, and a poly(A) tail at the 3’ end of the mRNA, each of which 
can be bound by specific proteins.  Animal replication-dependent histone mRNAs are the 
only known cellular mRNAs that do not end in a polyA tail.  In animal cells the replication-
dependent histone mRNAs are capped at the 5’ end (as are all RNA polymerase II 
transcripts), but instead of ending in a poly(A) tail, they end in a conserved stemloop 
sequence which is bound by the stemloop binding protein (SLBP) (Marzluff et al., 2008).  
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There are multiple potential pathways for degrading an mRNA (Parker and Song, 
2004; Schoenberg, 2011; Schoenberg and Maquat, 2012).  The three major pathways involve 
degradation starting at one of the two ends or by cleavage in the body of the mRNA.  
Degradation from the 3’ end involves deadenylation followed by 3’ to 5’ degradation by the 
exosome; degradation from the 5’ end starts with decapping (either before or after 
deadenylation) followed by 5’ to 3’ degradation by XRN1.  Endonucleolytic cleavage can 
involve cleavage by a specific endonuclease, siRNA mediated cleavage by the Ago protein in 
the RISC complex (Liu et al., 2004), or cleavage by SMG6 as part of the NMD mechanism 
(Eberle et al., 2009; Huntzinger et al., 2008), followed by subsequent exonucleolytic 
degradation of the fragments.  These fragments could be deadenylated and/or decapped as 
well.  An mRNA can also be degraded from both ends simultaneously (e.g. 5’ to 3’ by Xrn1 
and 3’ to 5’ by the exosome).  Histone mRNA molecules that likely arise by simultaneous 
degradation from the two ends of the mRNA have been identified by circular PCR (Mullen 
and Marzluff, 2008).   
mRNAs also can transition between actively translating forms and inactive forms of 
the mRNA, which are not translatable (Coller and Parker, 2005).  These include deadenylated 
mRNAs (which end in a short oligo(A) tail), which in animal cells is too small to bind PABP.  
Some mRNAs, like the ferritin mRNAs, may bind a specific protein in the 5’ UTR that 
blocks translation and this binding is reversible by addition of iron (Gray and Hentze, 1994).  
Deadenylation of an mRNA, resulting in a short oligo(A) tail which cannot bind PABP, 
inactivates translation of the mRNA and may promote binding of the Lsm1-7 complex as 
well as translational inhibitors such as Dhh1 (Rck/p54) helicase in animals) (Coller and 
Parker, 2005).  The inactive forms of mRNAs can be subsequently reactivated, by removal of 
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inhibitory proteins or miRNAs, together with cytoplasmic polyadenylation.  Untranslated 
mRNAs may accumulate in stress granules (Buchan and Parker, 2009), at the synapse in 
neurons (Giorgi et al., 2007), in the p granules in early embryos, where they may be bound 
by specific sets of proteins.  Binding of the RISC/miRNA complex to an mRNA blocks its 
translation, and stimulates deadenylation, which does not always lead to degradation of the 
mRNA.  There are also examples of proteins that bind to the 3’ UTR inhibiting translation.  
Regulation of translation is the most important regulatory mechanism in cells that aren’t 
synthesizing RNAs, including oocytes, early embryos, spermatids, and nerve cells, where 
translation at the synapse is tightly regulated.  Part of this regulation can involve 
modification of the mRNA, e.g. histone mRNAs are oligoadenylated in Xenopus oocytes and 
eggs (Ballantine and Woodland, 1985; Sanchez and Marzluff, 2004), which is one factor that 
blocks their translation. 
 
Modification of the 3’ End of RNAs 
 While most RNA molecules are a faithful copy of the DNA template, there are many 
RNAs where the 3’ end can be modified by addition of non-templated nucleotides. These 
include the polyadenylation of mRNA in eukaryotic cells, the addition of the CCA end to 
many tRNAs, either when the CCA is not templated in the DNA, or if it is lost from the 
tRNA, and oligoadenylation of the 3’ end of many defective RNAs by the TRAMP complex 
as a quality control mechanism in cells.  Many RNAs can also be uridylated, including 
miRNAs and pre-miRNAs, as well as polyadenylated mRNAs, which are often uridylated 
after deadenylation to shorten the polyA tail (Chang et al., 2014; Rissland and Norbury, 




Fig. 2.1.  Histone mRNA 
metabolism.   
A. Cell cycle regulation of 
histone mRNA.  Histone 
mRNAs accumulate at high 
levels only in S-phase.  When 
DNA synthesis is inhibited in 
S-phase, histone mRNAs are 
rapidly degraded.  Histone 
mRNAs are also rapidly degraded at the end of S-phase, and histone mRNA biosynthesis is 
down-regulated. B.  Structure of the histone mRNP.  Histone mRNAs are capped and end in a 
conserved stemloop sequence at the 3’ end which binds to both SLBP and 3’hExo.  C.  
Histone mRNA is formed by an endonucleolytic cleavage 5 nts after the stemloop, which 
requires SLBP, that binds the stemloop and U7 snRNP complexed with FLASH and the 
Histone Cleavage Complex (HCC) which contains the endonuclease CPSF73.  After 
processing, 3’hExo binds and trims 2 nts from the 3’ end.  In the cytoplasm during S-phase, 
there may be some trimming of the 3’ end, and the 3’ end is restored to 3 nts after the 
stemloop by uridylation.  When DNA synthesis is inhibited, 3’hExo can degrade into the 





polymerase, and can also have random extended tails added by polynucleotide phosphorylase 
(Kushner, 2004).  Both these 3’ extensions promote degradation of the mRNAs.  
Histone mRNAs are the only known mRNAs in animal cells that are not 
polyadenylated, ending instead in a conserved stemloop (Fig. 2.1). Histone mRNAs are also 
cell-cycle regulated being present only in S-phase when DNA is being replicated.  Regulated 
degradation of histone mRNA is an important regulated step in histone mRNA metabolism.  
Histone mRNAs are rapidly degraded when DNA replication is inhibited during S-phase and 
also at the end of S-phase when DNA replication is completed (Marzluff et al., 2008).  We 
found several years ago that histone mRNAs are uridylated at the 3’ end when histone 
mRNAs are being degraded (Fig. 1)(Mullen and Marzluff, 2008).  We subsequently showed 
that there is also uridylation to maintain the proper length of the 3’ end of histone mRNA 
during S-phase before degradation begins (Lackey et al., 2016; Welch et al., 2015).  Because 
of the natural coordination of   degradation of multiple histone mRNAs, they provide an 
excellent system for identifying degradation intermediates. 
 
Studying mRNA Degradation 
 Measuring mRNA half-life requires that one determine the change in concentration of 
the mRNA as a function of time after stopping synthesis of that mRNA.  Ideally one would 
do this by stopping biosynthesis of a specific mRNA and then watch its decay, without 
changing the metabolism of many other mRNAs.  There are several reporter systems that 
allow one to do this.  One system, pioneered by Shyu and Belasco, is to use the Fos promoter 
to drive expression of the mRNA (Shyu et al., 1989).  When Fos expression is activated there 
is a burst of FOS mRNA synthesis and then Fos transcription is repressed as a result of Fos 
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accumulation.  The mRNA then decays in the absence of any new synthesis.  A second 
approach is similar and uses the TET-on system (Chen et al., 2007).  Stable cell lines 
expressing the TET repressor are constructed (and some are commercially available), and 
expression of mRNA can be initiated by adding tetracycline/or a similar promoter (e.g. 
estrogen responsive promoters).  A more recent (and more global) approach to mRNA half-
life is to “pulse-label” cells with a modified nucleoside (e.g. thiouridine (Herzog et al., 2017; 
Rutkowski and Dölken, 2017) or bromouridine (Paulsen et al., 2014; Yamada et al., 2018) 
and then chase with uridine).  The RNA containing the modified nucleotide is purified and 
subjected to RNA-Seq analysis.  This allows determination of relative half-lives of all the 
RNA species, and is certainly the current best method to measure the half-lives of different 
RNA species, with minimal disruption to the metabolism of the cell.  Determining the precise 
structure of mRNA degradation intermediates is more difficult.  The above approaches allow 
you to detect some mRNA degradation intermediates, for example the formation and ultimate 
disappearance of deadenylated mRNAs, but detailed information on the precise sequences at 
the 3’ ends of the mRNAs cannot be determined without high-throughput sequencing, using 
strategies specifically designed to determine the ends of the RNA molecule.  
 
Histone mRNAs 
We have studied the metabolism of replication-dependent histone mRNAs.  These 
mRNAs are tightly cell-cycle regulated and are present in high concentrations only in S-
phase.  Instead of a polyA tail they end in a conserved stemloop, consisting of a 26 nt 
sequence a six base stem and four base loop, and the 5 nts flanking the stemloop.  Histone 
mRNAs also lack introns.  A critical regulatory step in cell-cycle regulation of histone 
34 
 
mRNA is rapid degradation of histone mRNA at the end of S-phase.  Histone mRNAs are 
also rapidly degraded when DNA replication is inhibited in S-phase.  Alteration of histone 
mRNA half-life is a mechanism the cell uses to rapidly adjust histone mRNA levels to 
provide appropriate amounts of histone mRNA for synthesizing the histone proteins 
necessary to package the newly replicated DNA.     
There are multiple histone genes encoding each of the 5 histone proteins in mammals.  
These genes are not repeated but each gene has a unique sequence, particularly in the 5’ and 
3’ UTR (Marzluff et al., 2002).  There are 10-15 distinct genes for each of the four 
nucleosomal core histones, and 5 histone genes encoding histone H1 all of which are 
coordinately degraded.  Histone mRNAs make up about 5% of the total mRNAs in S-phase 
cells. 
The conserved 26 nts sequence at the 3’ end of the mRNA is the cis element 
determining the regulation of the half-life of histone mRNA (Pandey and Marzluff, 1987).  
Translation is required for histone mRNA degradation, and the position of the stemloop 
relative to the stop codon is also critical for regulating degradation (Graves et al., 1987; 
Kaygun and Marzluff, 2005a).  The stemloop is normally present starting 20-60 nts after the 
stop codon.  If the stemloop is moved to 200 nts after the stop codon or replaced by a polyA 
tail, then the mRNA is no longer rapidly degraded when DNA replication is inhibited or at 
the end of S-phase.  The protein SLBP binds to the 3’ end of all histone mRNAs, and no 
other cellular mRNAs (Brooks et al., 2015).  SLBP is required for histone pre-mRNA 
processing in the nucleus and remains with the mRNA as it is exported to the cytoplasm, and 
is essential for histone mRNA translation (Sanchez and Marzluff, 2002).  Thus, like 
polyadenylated mRNAs, the 3’ and 5’ ends of the RNAs interact with the translation 
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initiation factors, creating a circular mRNP ribosome complex.  This complex is the initial 
substrate on which mRNA degradation is initiated.      
Early studies by Jeff Ross and coworkers suggested that histone mRNA degradation 
initiated at the 3’ end, and they identified a polysome-associated 3’ to 5’ exonuclease which 
would partially degrade into the stemloop (Caruccio and Ross, 1994; Ross and Kobs, 1986; 
Ross et al., 1986).  This protein was almost certainly 3’hExo, which was subsequently 
purified as a protein that bound to the histone 3’ end together with SLBP (Dominski et al., 
2003).  RNAi experiments implicated several factors in histone mRNA degradation, 
including Upf1, the NMD factor; Lsm1, part of the Lsm1-7 ring, which binds the oligo(A) 
tail on deadenylated mRNA; and the exosome, a processive 3’ to 5’ exonuclease.  There was 
a smaller effect of knockdown of enzymes involved in 5’ to 3’ decay, dcp2 or xrn1 (Mullen 
and Marzluff, 2008).  These RNAi experiments certainly aren’t definitive, since knockdown 
of 3’hExo had no effect on histone mRNA degradation (Dominski et al., 2003; Mullen and 
Marzluff, 2008), although subsequent knockout of 3’hExo showed it was essential for histone 
mRNA degradation (Hoefig et al., 2013). 
In our earliest attempts to isolate some histone mRNA degradation intermediates we 
used circular-RT-PCR (Mullen and Marzluff, 2008).  This method assumes the mRNAs have 
been decapped (or cleaved) and have a 5’ phosphate on the 5’ end.  The mRNA intermediate 
can then be circularized with RNA ligase, and detected by qRT-PCR, and the PCR products 
cloned and sequenced, which allows identification of the 5’ and 3’ end of the mRNA.  These 
sequences revealed the surprising finding that there were a number of degradation 
intermediates which ended in oligo(U) tails, most of which were in the stemloop (Fig. 2.1).  
The 5’ ends of these intermediates were also partially degraded, indicating that the RNA 
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molecules might be being degraded simultaneously 3’ to 5’ and 5’ to 3’.  Priming cDNA with 
oligo(A) primers confirmed that the histone mRNA degradation intermediates containing 
oligo(U) tails were present only after inhibition of DNA replication or at the end of S-phase 
(Mullen and Marzluff, 2008).  The yield of these intermediates was low and only a few 
molecules (~100) containing oligo(U) tails were obtained over several experiments, not 
enough to elucidate a pathway of degradation.  The oligo(A) priming experiments also did 
not allow us to determine the length of the oligo(A) tail and restricted us to identifying tails 
that were at least 3 nts long.   
We developed the method described below to determine the 3’ ends of histone 
mRNAs by high-throughput sequencing and to simultaneously identify any non-templated 
nts present at the 3’ end.  This method makes use of the approaches developed by Tuschl and 
coworkers (Hafner et al., 2008) and Hammond (Newman et al., 2011) to study miRNAs and 
pre-miRNAs.  A modification of this method allows us to enrich for transcripts which have 
specific non-templated nts at the 3’ end, by using a cDNA primer which contains 3 additional 
nts (e.g. 3 A’s to identify oligo(U) tails).   
 
MATERIALS AND METHODS 
 
Overview 
The goal of the EnD-Seq protocol is to determine the precise 3’ end of an RNA 
molecule, including any non-templated nucleotides that may be present on the 3’ end.  A 
synthetic linker (chosen to not cross-react with other sequences in the organism being 
analyzed) is ligated to the 3’ end of all cellular RNAs.  To prevent ligation of cellular RNA 
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molecules to each other, the linker is chemically modified by addition of App to the 5’ end 
allowing ligation to occur in the absence of ATP.  The linker also ends in an amino group 
rather than an OH, preventing ligation of the 3’ end of the linker.  cDNA is synthesized from 
the modified RNA using the reverse complement of the linker as a primer.  Subsequent 
amplification can be used to prepare sequencing libraries, and the 3’ ends are sequenced 
using standard sequencing protocols on an Illumina MiSeq.  Following sequencing the 3’ 
ends can be mapped to the genome using the AppEnd informatics programs (Welch et al., 
2015) which identifies both the template 3’ end of the RNA and any additional non-









Fig. 2.2.  Overview of the EnD-Seq/AppEnd workflow.  
A.  Total cellular RNA (or RNA from any subcellular fraction of interest) is ligated to a pre-
activated synthetic linker sequence which is added to the 3’ OH on all RNAs.  Note if the 3’ 
end is further modified (e.g. 2’Omethyl or phosphorylated) those ends will not be ligated. An 
oligonucleotide complementary to the linker is used to prime cDNA synthesis via reverse 
transcription.  Specific sets of mRNAs can be amplified by PCR to specifically amplify the 3’ 
ends of the mRNAs of interest.  The linker and gene specific primers are used to initially 
amplify the cDNA and a second round of PCR is used to add indices for each library and 
adapters for deep sequencing. Read 1 includes the linker sequence and 3’ terminus of the 
RNA and Read 2 includes the library indices and the gene sequence.  The reads are aligned 
to a reference genome, the linker sequence is identified using the AppEnd algorithm (Welch 
et al., 2015).  Any nontemplated nucleotides on the 3’ termini (as small as one nt) will be 
identified as nts between the last template nucleotide and the start of the linker (example 1). 
B.  One can also select for specific non-templated nts (e.g. 3 uridines) at the 3’ end by adding 
3 A’s to the 3’ end of the cDNA primer, followed by amplification of the cDNA for 
sequencing as in panel A.  Note that this will allow one to determine the length of the 
oligo(U) tail (example 2).  Note that if one primes at a template U or U’s, the AppEnd 
algorithm will identify only the non-templated nts as part of the tail (example 3).  We have 
observed mispriming at stretches of U’s, and these will be scored as no U tails (example 4).  
This method does an excellent job of identifying non-templated oligo(U) tails >2, and any 




Activation of the linker:  A synthetic oligonucleotide containing a 5’ phosphate and 
3’ amino group (to prevent ligation of the linker to other phosphorylated nucleotides) can be 
purchased from .a variety of vendors.  An activated linker can be purchased from NEB (Cat. 
# S1315S) but if you are doing a large number of experiments and need flexibility in linker 
design it is cost-effective to synthesize your own.  An alternative approach to the chemical 
approach described below is to use the 5’ DNA adenylation kit from NEB (M2611A) to 
synthesize an adenylated linker starting with a 5’ phosphorylated DNA, and an RNA ligase. 
The advantages of this kit are that it is easy to perform and adenylation efficiency is high, 
and it does not require further purification of the adenylated oligonucleotide.  The kit can 
synthesize enough adenylated oligonucleotide for 5-10 libraries.  Companies that provide 
synthetic oligonucleotides (e.g. Integrated DNA Technologies) will also sell activated 
oligonucleotides for a substantially higher cost.  Note that the actual sequence of the linker is 
not important, as long as it will not prime cDNA synthesis of other mRNAs.  The linker 
made by NEB (Cat. # S1315S) worked satisfactorily in a preliminary experiment.   
The chemical activation of the linker requires the synthesis of ImpA (adenosine 5'-
phosphorimidazolide) by exchange coupling an imidazole group onto the 5’ phosphate of 
5’AMP.  The ImpA molecule can then be coupled to the 5’phosphate (pN) on the linker, 
resulting in AppN as the 5’ end of the linker.  This is the activated product of the first step of 
enzymatic ligation reactions. We use a 26 nt linker, which contains a sequence designed to 
amplify the cDNA for sequencing with Illumina primers, and also include the linker 
sequence on the 3’ end of all sequencing reads, an essential part of the procedure to 
accurately map the 3’ end as well as nontemplated nucleotides.  
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Generation of cDNA.  The adenylated Linker is ligated to cellular RNA samples 
using a special T4 RNA ligase (Truncated Mutant K227Q) that ligates the activated AppNn 
oligonucleotide to the 3’ end of RNA in the absence of ATP. Once ligated, the linker 
sequence can be used as a primer site for reverse transcription.  Using Super Script III and a 
primer specific to the 3’ Linker sequence, reverse transcribe the RNA to cDNA. Take a 
portion of the cDNA and use it for the first step of PCR amplification using the linker 
sequence as the 3’ primer and a gene specific 5’ primer, in our case a primer for the various 
histone genes. We have found that we can use multiple gene specific primers per PCR 
reaction to increase the number of RNAs analyzed in each experiment. Following the first 
round of PCR (PCR1), we continue with the second round of PCR (PCR2). The second 
round of PCR is to add on sequencing handles/adapters and barcodes for the MiSeq.  
After amplification, we confirm library quality using a Bioanalyzer (Agilent 2100 
Bioanalyzer) and quantify using a QuBit (Ver. 2.0 Fluorimeter).  We sequence the libraries 
on a MiSEQ.  Note that you have to add a custom primer to the MiSeq chip for this 
sequencing protocol. We have used a variety of MiSeq chips for sequencing, and prefer the 
chips that give 2 x 75 or 2 x 150 nt reads.  The shorter MiSeq kit (V3-150) has consistently 
provided 30 million reads per kit, greatly increasing both the depth and multiplexing capacity 
of libraries.  After sequencing, we analyze the libraries using the AppEnD workflow (Welch 







Synthesis of ImpA 
 This synthesis involves the use of flammable solvents and oxidizing agents and 
appropriate care should be taken during the synthesis.  This is a straightforward synthesis for 
any chemistry laboratory with experience in organic chemical synthesis. 
 The following protocol has been adapted from the method of Hafner and coworkers 
(Hafner et al., 2008). Special care is taken to keep everything anhydrous. Failure to do so 
results in drastically lower yields of ImpA.  If the product is stored at -20oC as described 
below, it is good for at least a year, and provides enough IMP to synthesis at least 1 
micromole of adenylated oligonucleotide.  
All steps were conducted in a fume hood.   
1. Dry two 50mL glass flasks with a 140oC drying oven. Move flasks to fume 
hood and flush with argon gas. Seal flasks with septum and flush further with 
argon gas via a balloon and needle along with a second needle to allow air and 
excess argon out of the flasks. Allow the flasks to cool to room temperature. 
2. Suspend 174 mg of 5’ AMP free acid (Sigma-Aldrich A2252) in 15 mL of 
anhydrous dimethylformamide (Sigma-Aldrich 227056) in one of the round-
bottom flasks. The AMP will not dissolve entirely.  
3. In the other flask, dissolve 262 mg of triphenylphosphine (Sigma-Aldrich 
T84409), 220 mg of 2,2’-dipyridyldisulfide (also found as Aldrithiol-2, 
Sigma-Aldrich 143049) and 170 mg of imidazole (Sigma-Aldrich I5513) in 15 
mL of anhydrous dimethylformamide and 0.9 mL of triethylamine (Sigma-
Aldrich T0886).  
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4. Add the AMP solution/suspension dropwise to the vigorously stirring 
triphenylphosphine containing solution at 4oC. Stir the reaction for another 3.5 
hours at room temperature, keeping the flask sealed with a rubber septum. The 
5’ AMP from the dimethylformamide solution/suspension will dissolve 
completely and the solution should turn to a clear yellow-green color. 
5. Precipitate the ImpA by adding the reaction mixture dropwise into a 500 mL 
beaker containing a vigorously stirred solution of 1.1 g of sodium perchlorate 
(Sigma-Aldrich SX0692), 110 mL anhydrous acetone (Sigma-Aldrich 
650501), and 55 mL anhydrous diethyl ether (Sigma-Aldrich 296082). 
Precipitate will appear immediately and the solution will become cloudier as 
the whole reaction mixture is added. 
6. Stop stirring to allow the precipitate to settle to the bottom of the beaker. After 
1-2 hours, decant as much as possible of the supernatant without dislodging 
the precipitate. Once most of the supernatant is decanted, use a pipette to 
remove as much of the clear supernatant as possible. If precipitate is agitated, 
let sit for another 30 minutes to settle before pipetting.  
7. Once the volume has been reduced to about 20 mL, resuspend the precipitate 
in the residual supernatant and transfer to two dried 30 mL Corex glass 
centrifugation tubes. Rinse the beaker with two small volumes (5 mL each) of 
acetone and combine the wash solutions with the suspension already 




8. Pour off the supernatant and wash the pellet twice by resuspending it with 20 
mL acetone in the Corex tubes, followed by 5 minute centrifugation at 3000 
rcf. The pellet should be white and supernatant clear. 
9. Resuspend the pellet in 10 mL anhydrous diethylether and immediately collect 
it again by centrifugation at 3000 rcf for 20 minutes. Pour off the diethylether 
supernatant. Seal the centrifugation tubes with a septum and insert two 
needles. Use a balloon of argon gas to carefully flush the tube with argon to 
remove excess air, and then remove the balloon. Let the pellet dry overnight 
in a dessicator filled with DrieRite. 
10. Quickly transfer the flaky white powder to two small glass vials (one for each 
Corex tube) and use the same method as above to carefully exchange the air 
with a balloon of argon gas via a rubber septum. Seal with a screw-top lid and 
determine the mass of the product (minus initial weight of screw-top vial) to 
determine percent yield. Our yields were typically about 75%.  Wrap the lid 
with parafilm and place in glass container of DrieRite. Seal the glass container 
with more parafilm and store at -20oC.  We have successfully used it a year 
after synthesis when stored as described.  
11. The purity of the product can be monitored by thin-layer chromatography as 
described by Hafner and coworkers (Hafner et al., 2008). 
 
Adenylation of Linker Sequence with ImpA 
 For adenylation we use a 300:1 molar ratio of ImpA:Linker and a 150:1 molar ratio of 
MgCl2:linker.  Typically we first weigh the ImpA rapidly, to avoid it picking up water, by 
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adding to a tared microfuge tube.  The exact amounts do not need to be precise, since the 
volume of linker can be adjusted appropriately.  We have observed identical results with 
150:1 and 300:1 molar ratios of ImpA:Linker.  The linkers were synthesized by IDT, 5’ 
phosphorylated and 3’Amino modified (/5Phos/ and /3Ammo/).  We purchased 250 nmole of 
linker with standard desalting. A similar adenylated linker is available from NEB (Cat. 
#S1315). Note that the NEB linker is only 17 nt long, but is identical to the 5’ end of our 
linker sequence.  All the suggested RT and PCR primers will work with the NEB linker. . 
1. Add about 13.6 mg solid ImpA (~30 µMol) to a microfuge tube. We have 
used 6-14 mg with similar results.  The important parameter is to have ImpA 
in great molar excess to the linker) 
2. Add 85 µL of 1.25mM Linker Oligonucleotide dissolved in nuclease free 
water (~100 nmol) to the ImpA in a 1.5mL microcentrifuge tube.   
3. Add 16 µL of 1M MgCl2 in nuclease free water (16 µMol) to the microfuge 
tube.   
4. Add 399 µL H2O to give a final volume of 500 µL.  The ImpA dissolves 
readily in the water.   
5. Incubate 50oC 3 hours in water bath in tube sealed with parafilm 
6. Add 500 microliters of Formamide based RNA Dye without Xylene Cyanol 
(98% deionized Formamide, 0.025% SDS, 0.5mM EDTA pH 8.0, 0.025% 
Bromophenol Blue) and store at -20oC until ready to purify on the gel. 
7. Prepare a Medium (195 mm x 160 mm gel, 2 mm thick) sized Urea PAGE Gel 
19% Acrylamide-1% bisacrylamide. 
• 24g Urea 
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• 25mL 40% Acrylamide Solution (National Diagnostics AccuGel 19:1 
40%) 
• 5mL 10x TBE Buffer (500mM Tris, 500mM Boric Acid, 10mM 
EDTA pH 8) 
• Add H2O to 50 mL total volume 
• Add 500µL 10% APS (Ammonium Persulfate m/v) 
• 50µL TEMED 
• Dissolve urea in the acrylamide-buffer solution (a small amount of 
additional water may be required to fully dissolve urea) then continue 
to add water to a total volume of 50 ml, add APS and then 
immediately add TEMED to initiate polymerization, and cast gel 
(polymerizes in less than 1 minute).    
8. Run a control of Linker (not adenylated) to confirm the 1nt size shift along 
with 500uL of reaction (may take multiple gels to purify the whole reaction, 
depending on the yield and well size).  We use (1.5. mm thick) combs with 1 
cm teeth and load about 40-50 microliters (about 35-40 micrograms 
oligonucleotide) per well (see Fig. 2.3). 
9. Run gel at 450 volts for 4-5 hours (or until bromophenol blue dye runs off) 
and then run 30 minutes longer after dye runs off. If dye runs off in less time 
or more time, reduce or extend the extra run time respectively.  
10. Stain gel in ethidium bromide and 1x TBE solution (enough EtBr to produce a 
pale yellow color, 20-100µL per Liter of 1xTBE) for 20 minutes rocking at 
room temperature. Destain 1 hour in 1xTBE rocking at room temperature. 
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11. Place gel on UV box to visualize bands using long wave UV light. 
Alternatively one can directly view the two linkers by UV-shadowing with a 
254 nM light. Two bands of similar intensity should be apparent in the 
adenylation reaction, only one band in the negative control (Fig. 2.3). Cut a 
slice of gel containing the slower migrating (top) band in the adenylation 
reaction taking care not to cut the bottom band. If another, third, faint band 
appears above the top, do not take that band either.  
12. Pass excised bands in gel through a 1mL syringe (no needle attached) to purée 
the gel into a fine slush. Add 4mL TE buffer (10mM Tris Base, 1mM EDTA, 
pH 8.0) and incubate overnight at 4oC rotating in a 15mL polypropylene 
conical tube. Seal with parafilm to prevent leaks. 
13. Prepare GenElute tubes (Sigma-Aldrich GenElute Agarose Spin Columns 
56500) by rinsing with 100µL TE buffer (use 6 tubes and the eluates will later 
be combined). 
14. Let the gel/TE mixture sit upright for 5 minutes so the gel pieces settle to the 
bottom. 
15. Load TE supernatant (minimize any small gel fragments that are taken up into 
pipette tip) onto GenElute tubes. Spin 18k rcf for 10 minutes at room 
temperature.  
16. Collect all run through in one 15mL conical tube; this solution has the 
adenylated linker. 
17. To concentrate the activated oligonucleotide, add 1 eq. volume of 2-Butanol 
to solution and sit at room temperature for 5 minutes. Two liquid layers 
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should form. Remove the top (butanol) later and discard. Note the volume of 
the bottom (aqueous) layer should be slightly reduced. 
18. Repeat the above step (adjusting for what 1 eq. vol is each time) until final 
volume of the bottom (aqueous) layer is 250-500µL (approximately 3-5 times) 
and transfer the bottom (aqueous) layer to a 1.5 mL microcentrifuge tube.  
This contains all the adenylated linker.  
19. Extract the aqueous solution containing the adenylated linker with an equal 
volume Phenol:Chloroform (1:1) and shake vigorously.  
20. Centrifuge the solution at 15K rcf for 15 minutes and carefully remove the top 
layer into a fresh microcentrifuge tube. 
21. Add an equal volume of isopropanol and 5µL of Glycoblue reagent (15 
mg/mL Invitrogen AM9515 glycogen with dye) to the top layer and 
precipitate (overnight at -20oC or 30 minutes to 1 hour at -80oC).  
22. Recover the adenylated linker by centrifugation at 15K rcf for 30 minutes at 
4oC. Remove the supernatant and add 200µL of cold 75% ethanol solution to 
resuspend pellet. 
23. Centrifuge at 15K rcf for 15 minutes at 4oC, remove the supernatant and air 
dry for 2 minutes at room temperature.  
24. Add 30µL nuclease free water and quantify the purified adenylated linker 
using a Nanodrop.  
Fig. 2.3. Purification of the activated linker.  Following 
the reaction of the linker with ImpA to form AppLinker, 
the activated linker is purified away from the starting 
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linker using a preparative 20% polyacrylamide gel.  The first two lanes are the 26nt linker 
sequence (10 and 5 micrograms).  In the next two lanes are 17 and 35 micrograms of the 
ImpA reaction.   The bottom band is the unadenylated linker, and the upper band is the 
adenylated linker which is excised.  We typically load about 35-40 micrograms, and obtain 
sufficient purity for library preparation.  There is often a third, fainter band (arrow) above 
the two major bands which we do not elute. 
 
RNA Preparation 
1. Note that it is essential that the RNA is not contaminated with any DNA or 
DNase (and obviously RNase).  RNA can be purified either from whole cells 
or from particular cell fractions (nuclei, cytoplasm, polyribosomes) after cell 
fractionation.  
2. Whole cell RNA is isolated from whole cells by treating a 10 cm plate with 
1mL Trizol reagent (Invitrogen/Fisher Sci. 15596026) after removal of media 
and washing with Tris-buffered saline (TBS  0.14M NaCl, 10mM Tris, pH 
7.6).  Don’t use PBS since residual phosphate can precipitate with ethanol 
after the RNA preparation.  Suspension cells can be harvested by 
centrifugation, washed with TBS, and then suspended in TBS (5-10x106 
Cells/250 µL), and the suspension added to 750 µL of Trizol.   
3. Incubate cells incubated with Trizol for ~15 minutes at 4oC rotating.  
4. Add 200µL chloroform per 1 ml of Trizol, vortex briefly, and centrifuge at 
15K rcf for 15 minutes at 4oC. 
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5. Carefully remove the upper layer and add 1 volume of isopropanol. Precipitate 
30 minutes at -80oC or overnight at -20oC. 
6. Spin RNA down 30 minutes 15K rcf at 4oC and remove sup.  
7. Add 500 µL 75% ethanol to wash the pellet and spin down pellet 15 minutes 
at 15K rcf 4oC.  
8. Remove supernatant and allow to air dry for 2 minutes. Remove any excess 
ethanol that collected at the bottom. Add nuclease free water to resuspend the 
RNA based on amount of cells harvested.  We use 80µL water to resuspend a 
confluent well of cells in a 6-well plate.  The typical yield is 20-40 
micrograms per well of a 6 well plate.    
9. Quantify RNA using a Nanodrop and run 1 µg of RNA on a 1% agarose gel to 
confirm quality and concentration. There should be clear 18S and 28S rRNA 
bands and no smearing indicative of degradation.  If you are working with 
very small amounts of RNA then you can analyze the RNA on a Qubit (Ver. 
2.0 Fluorometer) or on an Agilent Bioanalyzer.  Note at this point the RNA 
may still be contaminated with small amounts of nucleotides, and the 
absorbance readings don’t necessarily reflect the total amount of RNA. 
10. Treat the RNA with DNase to remove all traces of DNA.  If we have 
substantial amounts of RNA, we generally DNase treat 10-20 µg of RNA. We 
can start with about 1 µg of DNase treated RNA for a total cell RNA library 
prep; 5 µg if we are going to do a ribominus prep.   
• 10µL 10x RQ1 DNase Buffer (Promega M6101) 
• 10µL RQ1 DNase (Promega M6101) 
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• 10-20 µg RNA  
• H2O up to final volume of 100µL 
11. Incubate at 37oC for 30 minutes in a water bath 
12. Add 400 µL of Phenol:Chloroform (1:1) to reaction and centrifuge at 15K rcf 
for 15 minutes at 4oC 
13. Remove the top layer and then an equal volume of isopropanol. Store at -80oC 
30 minutes or at -20oC overnight to precipitate RNA. 
14. Centrifuge 30 minutes at 15K rcf 4oC, remove sup 
15. Wash pellet with cold 75% ethanol and centrifuge for 15 minutes at 15K rcf 
4oC, remove supernatant and air dry 2 minutes 
16. Resuspend in 20 µL nuclease free water and quantify using a Nanodrop.  
Check the quality of the DNAse treated RNA on a Qubit (Ver. 2.0 
Fluorometer). 
 
Ligation of Adenylated Linker to RNA 
The goal of this step is to add to the linker to the 3’ end of every RNA molecule in the 
sample.  Note that ligation requires a free 2’ and 3’ hydroxyl.  RNAs ending in a 2’, 3’ or 
cyclic phosphate (e.g. 5’ tRNA halves) or in a 2’O-methyl nucleotide (some miRNAs) will 
not be ligated. If we are going to do a Ribominus preparation, we still ligate to total RNA 
prior to carrying out the depletion.    
1. Ligation Reaction:  (final volume 10 l) 
• 1-1.5 µg RNA treated with DNase 
• 500ng Adenylated Linker (about 50 picomoles) 
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• Add Nuclease Free Water up to total volume of 8 µL 
• Incubate at 65oC 15 minutes to denature the RNA, then put on ice for 3 
minutes 
• 1 µL10x T4 Ligase Buffer (NEB M0351S) 
• 1 µL T4 RNA Ligase 2, Truncated K227Q (NEB M0351S) 
• Incubate at 16oC overnight (up to 24 hours) 
• Reaction can be stored at -20oC at this point.   
2. Purify ligated RNA by adding 90 µL water and 100 µL Phenol:Chloroform 
(1:1) 
3. Shake vigorously and spin 12k rcf for 10min 4oC. 
4. Remove the top layer.  Add 100 µL Chloroform , shake vigorously, and spin 
12k rcf for 10 min 4oC 
5. Remove the top layer and add an equal volume of isopropanol and 1 µL 
Glycoblue  {15 µg, Invitrogen AM9515) 
6. Precipitate at -80oC for 30 minutes 
7. Centrifuge at 15K rcf for 30min at 4oC, remove supernatant. 
8. Wash with 200 µL 75% ethanol, centrifuge at 15K rcf for 15 min at 4oC, 
remove supernatant and air dry 2 min 
9. Remove any excess ethanol that collected and add resuspend RNA in 10 µL 
water.  
Store at -20oC until ready for Reverse Transcription.  We generally transcribe the 






1. Add 5 µL of 10µM RT Primer specific to the Linker sequence to the 10 µL of 
ligated RNA from the previous step 
2. Incubate at 65oC for 15 minutes to denature, then on ice for 3 minutes 
3. Add 1 µL 10mM dNTPs (NEB N0447S) 
4. Add 5 µL 5x RT Buffer (Invitrogen 18080093) 
5. Add 1 µL 0.1M DTT (Invitrogen 18080093) 
6. Add 2 µL water 
7. Add 1 µL SuperScript III (Invitrogen 18080093) 
8. Mix by pipetting and incubate at 50oC for 1 hour followed by 65oC for 20 
minutes to inactivate SuperScript III 
9. Store cDNA (25 µL total) at until ready for PCR amplification of library. We 
have stored cDNAs for 6 months to a year at -20oC for 6 months to a year.   
 
PCR 1 (Library Amplification) 
1. PCR Reaction 
• 5 µL of cDNA (20% of total Reverse Transcription reaction) 
• 10 µL Q5 5x Buffer (NEB M0493S) 
• 1 µL 10mM dNTPs 
• 1 µL 10µM Linker Specific Reverse Primer 
• 1 µL 10µM Gene Specific Forward Primer (or 0.5 µL of two gene 
specific primers) Note one can multiplex as many gene-specific 
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primers as you want at this step.  The gene specific primers will each 
have an Illumina primer sequence at the 5’ end.  
• 0.5 µL Q5 Hot-Start DNA Polymerase (NEB M0493S) 
• 31.5 µL of water to bring volume up to 50 µL 
2. Cycle Details 
1. 95oC 3 minutes Heated Lid 
2. 95oC 15 seconds 
3. Annealing Temp (56oC for Histone primers) 15 seconds 
4. 72oC 15 seconds 
Repeat steps 2-4 for 15 cycles total 
5. 72oC 2 minutes 
6. 16oC Hold 
3. PCR Cleanup 
• Add 40 µL of Axygen PCR Mag Bead (Axygen/Fisher Sci. 14-223-
151 ) slurry to PCR1 
• Mix 10 times with pipetting 
• Let sit at Room Temperature for 10 minutes 
• Place on magnetic stand 5 minutes, remove supernatant 
• Add 200 µL 100% ethanol to the beads and resuspend thoroughly 
• Place on magnetic stand 5 minutes, remove supernatant 
• Add 200 µL 100% ethanol to the beads and resuspend thoroughly 
• Place on magnetic stand 5 minutes, remove supernatant 
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• Air dry 7-10 minutes, until Mag Bead pellet is no longer shiny, but has 
not cracked yet. 
• Add 20 µL water and resuspend thoroughly 
• Place on magnetic stand 5 minutes 
• Carefully remove the supernatant and save for next step.  Be careful 
not to take any of the Mag Bead pellet 
4. Use a Qubit (Ver. 2.0 Fluorometer) High Sensitivity dsDNA kit to quantify 
PCR1 of library for quality control 
Note that the readings at this step may be very low.  There is no need to add more 
cycles to PCR1 unless the subsequent PCR2 step does not give any DNA. 
For example, a <0.1ng/µL reading does not mean PCR1 has failed if at least one 
library has a reading above 0.1ng/µL. We typically will make 5-10 libraries at once.   
 
PCR 2 (Sequencing Adapter Addition) 
• You can do only a single PCR if you design the initial PCR1 primers with 
miSeq adapters included.  In this case the oligonucleotides will be about 100 
nts for each index you have synthesized.  We elected to use a second PCR step 
to reduce the size of the primers.  Please ask if interested about the longer 
primers  
1. PCR Reaction 
• 15 µL PCR1 (about 2 ng maximum) 
• 1 µL 10mM dNTPs 
• 1 µL Distal Primer (10µM) 
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• 1 µL IR Indexing Primer (10µM) This is different for each library 
being made 
• 0.5 µL Q5 Hot Start DNA Polymerase 
• 10 µL Q5 5x Buffer 
• 21.5 µL H2O to final volume of 50 µL 
2. Cycle Details 
1. 95oC 3 minutes Heated Lid 
2. 95oC 15 seconds 
3. 56oC 15 seconds 
4. 72oC 15 seconds 
            Repeat steps 2-4 for 15 cycles total 
5. 72oC 2 minutes 
6. 16oC Hold 
3. PCR Cleanup 
• Identical to protocol for PCR1 Cleanup 
4. Use a Qubit to quantify PCR2 of library 
• Readings should be in the 10-50ng/µL range for ~500bp amplicon 
library preparations. If less than 5ng/µL, it may be necessary to 
concentrate the amplified DNA 
 
Library Quality Control 
 After recording concentrations of your library on the Qubit, load ~10ng onto a 
Bioanalyzer DNA Chip (Fig. 2.4). Ideally you should see only a clear band or clusters of 
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bands about 450bp for the histone mRNAs.  Note that the band is heterogenous, both because 
each histone mRNA has a slightly different length 3’ UTR and the amplified sample will 
contain all the degradation products as well as remaining full length RNA from multiple 
histone genes.  A band around 120 indicates you have primer dimers, which likely occurred 
during the second PCR amplification.  We will often simply repeat both the PCR1 and PCR2 
with the remaining cDNA which usually results in a successful library. Small amounts of this 
band (5% of total) do not interfere with successful library sequencing. The bead cleanup 
details provided are a strict bead wash that gets rid of most primer dimers.  
 
Fig. 2.4.  Quality Control of EnD-Seq Libraries.  The final libraries are analyzed on a 
Agilent Bioanalyzer.  About 10 ng of each sample (determined by the Cubit reading) is 
loaded in each lane.  Shown is a standard DNA Agilent Chip.  All the libraries we plan to 
multiplex are run on the same Chip.  The expected products are about 450 nts for full-length 
histone mRNAs, with shorter lengths for the degradation intermediates.  Primer dimers from 
PCR2 are about 120 nts and are a common contaminant.  The left lane is the provided ladder 
for determining library size. Lanes 2, 4, 5, and 8 excellent libraries with minimal primer 
dimers. Lanes 1 and 6 have some primer dimer contamination, but gave good results on 
sequencing.  Lanes 3 and 9 have excessive amounts of primer dimer.  This is generally 
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corrected by reamplifying the cDNA.   Lane 7 is a failed library, which may require starting 
from a new reverse transcription of the ligated RNA.     
 
MiSeq Run 
 We initially used the 300 v2 MiSeq kit which now typically yield about 20 million 
reads.  With the introduction of the 150 v3 MiSeq kit, we now typically obtain 30 million 
reads per flow cell, and sufficient read length to map the products.  Prepare the libraries by 
diluting each of your libraries (cleaned PCR2 reaction) to 2nM and follow the MiSeq 
preparation guidelines for the 2 nM library prep (not the 4 nM). Add 1 µL of each library to a 
small PCR tube to pool them all together (minimum of 5 µL final, but there is no maximum) 
and then being denaturing the libraries according to the MiSeq guidelines. The final pooled 
library concentration should be ~9-10 pM. 9 or 10pM library pools should be acceptable. If 
preparing libraries from a small number of target RNAs (as we do for the histone mRNAs), 
an additional library (with indices that do not conflict with your own) will be required in the 
pool to provide diversity in the sequencing reaction.  Otherwise the miSEq Chip may fail.  
Add 1 µL of this library (diluted to 2 nM) to the pool. We typically use a library from 
another species or a RNA-Seq library to provide the diversity. The diversity library can be as 
low as 7% of the total MiSeq run.  Add the PhiX DNA (provided by Illumina) to the libraries 
during the sample loading steps as indicated in the miSeq protocol so that the PhiX is 15-
30% of the total input.  
 After injecting the pooled library samples into Port 1 (sample port), be sure to add the 
primer that recognizes the EnD-Seq libraries into Port 12 (Read 1 Primer Mix port). Use a 10 
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µL pipette with thin gel loading tips to add the primer.  The final concentration of the primer 
should be 0.5 µM (3 µL of a 100 µM stock of the sequencing primer).  
 
Data Analysis 
After running on the MiSeq, the libraries are analyzed using the AppEnD workflow 
(Welch et al., 2015). To display the results, each nucleotide is assigned an index, with the 3’ 
terminus of processed RNA being assigned index zero, which is plotted on the X-axis.  The 
Y axis indicates how many sequences end with that nucleotide as the final template 
nucleotide.  The stacked bar graph demonstrates whether there is no non-templated tails, one 
nontemplated nucleotide, two nontemplated nucleotides, or 2+ nontemplated nucleotides. In 
Fig. 2.5A, we show the 3’ ends of histone mRNA in S-phase.  Note that the template nts in 
the mRNA end at three different sites, but they all extend three nts past the stemloop, with 
the differences made up by non-templated uridines (Fig. 2.5A).  Thus the last 3 nts are AUU, 
ACU or ACC with ACC being completely templated.  Also shown are libraries prepared 
from synchronized cells treated with hydroxyurea (HU) focusing on two type of degradation 
intermediates: the intermediates in the stemloop (Fig. 2.5B), and the intermediates in the 3’ 
UTR through the stop codon (Fig. 2.5C).  After 15 minutes of treatment with hydroxyurea, 
we can see a build-up of degradation intermediates in the stemloop and the 3’ UTR (Fig. 
2.5B, C). When we prime using the dA primer (3 A’s on the Reverse Transcription primer) to 
identify only longer uridine tails found during degradation, we see an enrichment of these 
species in the stemloop (Fig. 2.5D) and there are very few long tails on the RNAs ending 
after the stemloop.  The intermediates in the stem are the predominant species.  Note that we 
see a substantial number of artifactual reads when we use the dA primer, including internal 
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priming at the 4 U’s in the loop (Fig. 2.2B), but these are removed during the analysis since 
they do not contain 3 non-templated nucleotides. 
From this data we can deduce that the pathway of histone mRNA degradation 3’ to 5’ 
has two major “kinetic” intermediates.  We see the same spectrum of intermediates when we 
analyze samples shortly after initiation of degradation (<10% of histone mRNA degraded) 
and when 60-70% of the histone mRNA has been degraded (Slevin et al., 2014).  This 
suggests that the rate limiting step in degradation (not surprisingly) is initiation of 
degradation, which in this case is degradation into the stemloop by 3’hExo (Fig. 1D), and 
that individual molecules are then rapidly degraded.  This results in accumulation of a 
steady-state distribution of intermediates which is maintained until the mRNA is degraded.  
If there are slow steps in degradation these will appear as an accumulation of reads at 
particular sites.  We see two kinetic intermediates in histone mRNA degradation: 1. 
Accumulation of uridylated intermediates after degradation 4 to 5 nts into the stem and 2. 
Accumulation of intermediates 15 nts 3’ of the stop codon, which are also uridylated (Fig. 
2.5E).  Intermediate 1 likely accumulates because SLBP is still bound to the 3’ end, and must 
be removed prior to further degradation.  Intermediate 2 likely results from the exosome 
reaching the stalled terminating ribosome.  There are intermediates throughout the coding 
region likely due to other ribosomes bound to histone mRNA. Before degradation can 




Fig. 2.5. Visualization of the Results.  The AppEnd algorithm includes mapping to the 
genome giving the position of the last templated nucleotide, and determining the length and 
composition of any non-templated 3’ tails on each read (Welch et al., 2015).  These can be 
used to create bar graphs.  We typically plot bar graphs showing the reads with 0 tails, 1 nt 
tails, 2 nt tails and greater than 2 nt tails as a function of position in the mRNA.  A. S-Phase 
cells obtained after double thymidine block and aligned to the 3’ termini of histone 
HIST1H2AG mRNA.  Index 0 corresponds to the last nt after processing.  The actual number 
of reads is shown on the Y-axis, and the number corresponding to the indicated percentage of 
total reads is also shown.  Plotting the percentage of total reads allows one to normalize 
between different libraries.  Note the major 3’ ends are ACC, ACU and AUU, each extending 
3 nts after the base of the stem.  B. The S-phase cells were treated with HU for 15 min to 
inhibit DNA replication, and the results plotted as in panel A.  Note that the major 3’ ends 
are the same since only a small fraction of the mRNA has been degraded. There are 
additional intermediates in the stem loop which contain a high fraction of tails >2 nts.  C. 
The data from the same library as in panel B is plotted for nts 20-150 (with the stemloop 
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removed to show the intermediates).  This shows there are very few intermediates present 
between the stop codon and the stem loop.  Starting 15-20 nts after the stop codon there are 
large number of intermediates, many of which are uridylated, indicating that the exosome 
has encountered the terminating ribosome, which stalls degradation.   D. The same RNA 
sample as in panel B was primed with a linker ending in three A’s.  Reads with >2 nt non-
templated tails are shown.  Note that the most abundant RNAs with long tails are in the stem.    
 
DISCUSSION 
 This approach can potentially give information about the 3’ end of every RNA in the 
cell.  Since degradation intermediates are likely to be present in very low concentrations, 
selecting a subset of mRNAs to analyze is the only possible way to obtain sufficient number 
of degradation intermediates to deduce the 3’ to 5’ degradation pathway of an RNA.  Note 
this method gives no information about the 5’ end of the degradation intermediates.  The fact 
that we were able to isolate some molecules by circular RT-PCR that were partially degraded 
from both ends suggests that decapping and 5’ to 3’ degradation also plays a role in histone 
mRNA degradation, and it is not possible to determine the relative importance of the two 
pathways.  We have shown that some of these degradation intermediates are capped (Slevin 
et al., 2014), suggesting that 5’ to 3’ degradation and 3’ to 5’ degradation is not occurring 
simultaneously on all the histone mRNA molecules.  These 3’ to 5’ degradation 
intermediates can be isolated from polyribosomes, consistent with degradation initiating and 
continuing on polyribosomal bound mRNP which has a stalled ribosome at the termination 
codon (Slevin et al., 2014).   
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 The degradation intermediates we can characterize by this approach are limited to 
molecules that can be amplified by using the primer in the coding region chosen for 
amplification.  This is about 270 nts from the 3’ end of the mRNA (about 200 nts from both 
the start codon and 200 nts from the stop codon) in our experimental design.  It is potentially 
possible to isolate intact histone mRNA degradation intermediates (e.g. by using a 
biotinylated antisense oligonucleotide identical to the primer for second strand cDNA 
synthesis) to isolate all molecules containing a central sequence of the histone mRNA in the 
coding region.  If one first ligates the 3’ linker onto the total RNA sample and then isolates 
the RNA using a biotinylated nucleotide, then one can ligate a different primer onto the 5’ 
end, using protocols to identify 5’ phosphorylated ends (Willmann et al., 2014; Yu et al., 
2016), or capped ends (Nechaev et al., 2010).  This would allow us to determine whether 
decapping occurs extensively on either intermediate 1 or on intermediates in the coding 
region.  
 This same approach can potentially be used to identify degradation intermediates on 
any mRNA. Elmar Wahle used a similar approach to detect degradation intermediates in 
Drosophila heat shock mRNA and observed non-templated A’s on some of the intermediates 











KNOCK OUT OF TUT7 AND 3’HEXO DEMONSTRATE ROLES IN STABILIZATION 
AND DEGRADATION OF HISTONE mRNA  
 
INTRODUCTION 
Replication-dependent histone mRNA levels are tightly regulated during the 
mammalian cell cycle, with histone mRNA accumulation occurring swiftly at the beginning 
of S-phase and histone mRNAs being rapidly degraded at the end of S-phase.  The bulk of 
this regulation is posttranscriptional, and is mediated through the novel 3’ end of histone 
mRNA (Harris et al., 1991).  Metazoan replication-dependent histone mRNAs are the only 
known cellular eukaryotic mRNAs that are not polyadenylated, ending instead in a conserved 
stemloop rather than a poly(A) tail (Marzluff et al., 2008).  Rapid degradation of the histone 
mRNA requires the stemloop at the 3’ end of the mRNA, and that the mRNA be translated 
(Graves et al., 1987; Kaygun and Marzluff, 2005a; Pandey and Marzluff, 1987).  Several 
years ago we reported that histone mRNAs were uridylated in the stemloop when 
degradation was activated, either by inhibiting DNA replication or at the end of S-phase 
(Mullen and Marzluff, 2008).  Subsequently we developed a sequencing pipeline for efficient 
detection or non-templated nucleotides on histone mRNAs, and found that histone mRNAs 




uridylation during S-phase keeps the 3’ end of the histone mRNA a constant length, ending 
three nucleotides after the stemloop.  The enzymes involved in the maintenance of the length 
of the stemloop are 3’hExo, a 3’ to 5’ exonuclease, which forms a ternary complex with the 
SL and SLBP at the 3’ end of histone mRNA (Tan et al., 2013; Yang et al., 2006) and a 
TUTase which adds additional U’s if 3’hExo digests too far to restore the length of the 3’ 
end.  3’ hExo can remove 2-3 nucleotides from the 5’ nucleotides extension after the stem, 
formed during histone 3’ processing by cleavage of the pre-mRNA 5 nucleotides after the 
stemloop (Yang et al., 2006).  Hoefig, Heissmeier and coworkers found that knock-out mice 
lacking 3’hExo did not rapidly degrade histone mRNA, implicating 3’hExo in the initial 
steps of histone mRNA degradation, which involves 3’ to 5’ degradation of histone mRNA 
into the stemloop (Hoefig et al., 2013).   
There are several terminal uridyl transferases, TUTases, which are members of a 
family of proteins that contain a non-canonical polyA polymerase domain (PAPD), including 
cytoplasmic polyA polymerases and nuclear polymerases of the TRAMP complex. This 
family of proteins has been recently renamed as the TENT family of proteins (Warkocki et 
al., 2018a).  The major cytoplasmic uridyl transferases (TUT4/TENT3A; and TUT7/TENT 
3B) are large (>1400 aa) proteins with a common domain structure (Faehnle et al., 2017; 
Warkocki et al., 2018a).  TUT7 has been implicated in histone mRNA uridylation using 
RNA interference and analyzing the changes in uridylation at the 3’ end and of degradation 
intermediates (Lackey et al., 2016).  Here I report the effect of knockout of TUT7 and 
3’hExo in HCT116 cells.  Knockout of TUT7 resulted in an 80% reduction of uridylation at 
the 3’ end of histone mRNAs, even although the TUT7 knockout cells had increased amounts 
of TUT4.  Uridylation of the degradation intermediates in the stemloop was completely 
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inhibited, and the overall rate of histone mRNA degradation was reduced but not abolished.  
Knockout of 3’hExo resulted in stabilization of histone mRNA, and more extensive 
uridylation of the 3’ end of histone mRNA.  Similar effects were seen in synchronized S-
Phase cells treated with DNA synthesis inhibitors and cells at the end of S-phase.  Although 
3’hExo KO stabilized histone mRNAs when DNA synthesis was inhibited, histone mRNAs 
were still degraded before mitosis in synchronized cells, suggesting there a second pathway 
to ensure histone mRNA degradation prior to mitosis. 
 
MATERIALS AND METHODS 
 
CRISPR Cas9 Knock Out 
 Two guides were designed to target Exon 2 of TUT7 downstream of the start codon 
to effectively disrupt the open reading frame. One guide was designed for Exon 2 of 3’hExo 
to also disrupt the ORF. Guide plasmids were transfected in equal mass with a FLAG-tagged 
CAS9 expression plasmid (Addgene#44758) and a GFP expressing plasmid (pmaxGFP from 
Lonza). Cells were sorted 3 days after transfection by FACS to produce three 96 well plates 
containing a single green cell in each well. Clones of cells were grown up and assayed by 
sequencing PCR Products from genomic DNA, and by western blotting. 
 
Cell Culture and Colony Selection 
All experiments were performed in HCT116 Colon Carcinoma cells. Cells were 
reverse transfected with Lipofectamine 2000 and 500ng/200k cells of Cas9, GFP, and gRNA 
expressing plasmids each. 3 days later GFP positive cells were selected by flow cytometry 
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and sorted into single cells per well in three 96-well plates. These cells were grown into 
monoculture colonies for approximately 3-4 weeks, expanding to larger well sizes as 
necessary, until all viable colonies were in 6-well plates. Approximately 10-15 colonies were 
obtained per plate.  
For cell cycle assays, cells were synchronized with a double thymidine block. 
Approximately 500,000 to 1 million cells were treated with Thymidine (final concentration 
[2mM]) in 6 well plates for 12 hours. Cells were then washed with PBS and fresh media 
without thymidine added and allowed to grow for 9 hours. A second thymidine block [2mM] 
was added for another 12 hours. Cells were then washed again with PBS and allowed to grow 
in thymidine-free media, and the cells entered S-phase rapidly after removing thymidine. 
Time points from the start of S-Phase were taken starting at the second release. Three hours 
into S-Phase, cells were treated with [5mM] Hydroxyurea (HU) and incubated for 20 or 40 
minutes to determine degradation of histone message.  The progression of cells through S-
phase was followed by flow cytometry.  Edu [100µM] was added 30 minutes before 
harvesting the cells to quantify cells synthesizing DNA. 
 
Western Blotting 
Cells were also collected for protein analysis by washing cells with PBS and treating 
with 500µL of Trypsin. After pelleting, the cells were treated with 0.5% NP-40 lysis buffer 
and 1mM PMSF on ice for 30 minutes. Samples were then spun down for 10 minutes at 4oC 
and the supernatant (cytosol) was saved and protein quantified via a Bradford Dye assay. 
Samples were run on 10% SDS PAGE for 3’hExo samples and 6% SDS PAGE for TUT7 
samples. 10-20µg of lysate were used for TUT7 and 3’hExo western blotting, while the 
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TUT4 western blot required 50-100µg of cell protein lysate. Antibodies for TUT7 (Protein 
Tech 25196-1) at 1:1k, 3’hExo (Gift from Xiaocui Yang (Yang et al., 2009)) 1:3k, TUT4 
1:500 (Protein Tech 18980-1), and the loading control β-Actin (Gene Tex GT5512) 1:10k or 
PTB (Mariano Garcia-Blanco) 1:2k were used in 5% milk and PBST. 
 
PCR Confirmation and Subcloning 
 Cells were recovered from 6-well plates as described in western blotting. After 
pelleting, about 200,000-500,000 cells were lysed with 200 µL 1% SDS buffer (10mM Tris 
pH 8.0, 100mM NaCl, 2.5mM EDTA) and 1 µL of Proteinase K (20mg/mL) at 50oC for 1-3 
hours. 200 µL of buffer-saturated Phenol:Chloroform (1:1) was added to extract DNA, 
vortexed briefly, and centrifuged 15 minutes at 15k rcf at 4oC. The supernatant aqueous layer 
was saved, and 1 equivalent volume of Isopropanol was added. Samples were then 
precipitated at -80oC for 30 minutes or -20oC overnight. Samples were then spun at 15k rcf 
for 30 minutes, the supernatant was removed, and then washed with 75% ethanol before 
spinning at 15k rcf for 15 minutes. DNA was then resuspended in 100-1000 µL of water and 
quantified via Nanodrop 2000.  
 DNA was amplified with primers equidistant from the targeted CRISPR guide 
sequence, to yield a 400-800bp amplicon. Q5 DNA polymerase was used to increase fidelity 
of the sequence and prevent PCR mutations when looking for heterozygous sequencing 
reads. The PCR products were sent for sequencing using one of the amplifying primers, or a 
nested primer for more challenging sequences to read across the targeted guide sequence. 
PCR samples that came back with strong single peaks and sudden heterozygous peaks (two 
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equal nucleotide peaks) at the guide location onwards in the chromatogram were identified as 
successful CRISPR mutations and prepared for western blot analysis (Fig. 3.1).   
 Lysates from cells with CRISPR events were assayed by Knock Outs were confirmed 
with western blotting to identify putative knockout cells.  The PCR amplicons from putative 
knockout cells were subcloned into pBlueScript II sk(+) via blunt cloning for identifying the 
mutations occur on each allele. Generally, a ligation ratio of 1:3 to 1:8 (excess insert) was 
used with 40 ng of cut pBlueScript II. One quarter of the ligation was initially transfected 
into 50 µL of competent DH5α cells. Ligation and cells were incubated for 30 minutes on 
ice, 42oC for 45 seconds, and then back in ice for 3 minutes before adding 500 µL of LB and 
shaking for 1-2 hours at 37oC. 20 µL of 1:1000 X-Gal was plated on Ampicilin resistant agar 
plates and warmed up before plating the entire transfection. Volume of transfection was  
Fig. 3.1. Heterozygote as 
Precursor for CRISPR KO 
of 3’hExo. A)Western blot 
confirming roughly half 
expression of 3’hExo in 
cell line “3h6” compared 
to Wild Type or un-altered 
cell lines. B) PCR 
Sequencing of “3h6” 
genomic DNA amplified 
around the targeted site 
shows editing near the 
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gRNA PAM site with double peaks appearing. Double peaks demonstrate a discrepancy 
between the two alleles. C) Subcloning sequencing confirms one allele of “3h6” is Wild Type 
(gRNA sequence boxed) and the other is missing the PAM site and portion of the 20nt 
recognition sequence.   
reduced by spinning 3 minutes at 1000 rcf at room temperature to pellet transfected cells 
after shaking. Blue colonies indicated that the plasmid re-ligated to itself and had no insert, 
where white colonies inserted the PCR product into the LacZ gene, disrupting the colony’s 
ability to cleave the X-Gal on the plate. 5-10 white colonies were picked for each knock out 
cell line and sequenced with both a T7 forward primer and a M13 reverse primer. Once both 
alleles are identified with frameshift indels, further assays on the validated knock out cell 
lines can proceed.  
 
Northern Blotting 
 RNA is isolated by adding 1mL of Trizol reagent directly to a 10cm dish, or 200µL of 
Trizol to a well of growing cells in a 6-well plate, ready for harvest. The RNA/Trizol is then 
rotated for 15 minutes at 4oC, 200 µL of chloroform is added, vortexed briefly, and then spun 
at 15k rcf for 15 minutes at 4oC. The aqueous supernatant is recovered and the RNA 
precipitated with 1 equivalent volume of isopropanol at -80oC for 30 minutes or -20oC 
overnight. RNA is spun down for 30 minutes at 15k rcf at 4oC, washed with 75% ethanol, 
and spun again for 15 minutes more. RNA is resuspended in 80 µL RNase free autoclaved DI 
water per confluent 10cm plate harvested, or roughly 20 µL of water per well of a 6-well 
plate. RNA was then quantified with nanodrop and water was added to adjust RNA to a 
concentration of 250-1000ng/µL.  
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 RNA concentrations and quality were confirmed by running 1 µg of RNA on a 1% 
agarose gel and comparing samples 18S and 28S rRNA bands, adjusting volumes as 
necessary to prepare equal loading. 5 µg of RNA was loaded on a pre-warmed 8% 8M Urea-
PAGE medium gel and a bromophenol blue/xylenol dyed loading buffer. RNA samples were 
run until both dye fronts ran off the gel, and then for 30 minutes longer at ~400-500V in 1X 
TBE buffer. Gels were transferred in 0.5X TBE buffer for ~50 minutes at 30V to HyBond 
positively charged membranes, dried, and cross linked three times using the Auto feature in a 
Stratalinker. 
 RNA probes were prepared with PCR products (for the histone HIST2H2AA3 gene 
or the 7SK gene) and a Klenow Fragment Radiolabeling Kit (Agilent’s Prime-It II Random 
Primer Labeling Kit). Approximately 1 µL of 7SK probe was used to probe 7SK, and 
~600,000 cpm of H2A probe for histone detection. Before hybridization, blots were pre-
hybridized with 5 mL of hybridization buffer (GE’s Rapid-Hyb RPN1636) rotating at 65oC 
for one hour. Blots were hybridized overnight in hybridization buffer at 65oC with the 
radioactive probes labeled. The following morning, blots are washed with 1xSSC and 0.5% 
SDS buffer. 40mL for the first wash for 30 minutes at 55oC, 20mL for the second and third 
wash, each wash for 30 minutes at 55oC. Wash blots are wrapped in plastic wrap and placed 
on film at -80oC with an enhancer screen for 1-5 days, or on a GE Typhoon Phosphorescent 
screen at room temperature in a cassette (in a dark location) for 4 to 48 hours.  
 
Flow Cytometry 
 Cells were removed from the dish using 0.5% Trypsin and spun down at 200 rcf for 3 
minutes, washed with PBS once, spun again, and resuspended in 1mL of 75% ethanol. 
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Samples can be kept for over one month at 4oC in this stage. Once ready for propidium 
iodide staining, cells are spun down at 200 rcf for 3 minutes, washed with PBS twice, and 
labeled for 1 hour at room temperature in the dark with 800 µL of 50µg/mL Propidium 
Iodide and 500U of RNaseA in PBS. Cells were then filtered through 40 µm cell filters and 
analyzed on a Beckman Coulter CyAn ADP. Gating for FS/SS, SS linear/SS area, and 
propidium iodide were used and analyzed with SUMMIT flow analysis software. 
 For EdU staining, a modified process was utilized. During synchronization, 30 
minutes prior to harvest time points, cells were treated with 100µM of EdU. All cells from 
the well were harvested, fixed in 0.5 ml 4% Formaldehyde in PBS for 15 minutes and then an 
equal volume of 1% BSA, and then stored at four degrees. All solutions used were in PBS. 
For analysis, cells were washed in a solution of 1% BSA and then resuspended in a solution 
of 1% BSA and 0.5% Triton X-100 for 15 minutes. Cells were pelleted and then suspended 
in 500µL of a solution of 1mM CuSO4, 1µM Alexa Fluor 647 Azide, 100mM Ascorbic Acid 
for 30 minutes in foil. 1mL of 1% BSA and 0.5% Triton X-100 was added and then cells 
were pelleted. Cells are resuspended in 500µL of 1% BSA, 0.5% Triton X-100, 1:1000 DAPI 
(100µg/mL stock, 0.1µg/mL final), and 40µg/mL RNase. Incubate with DAPI in the dark for 
one hour at 37oC before filtering and running on a CyAN Flow Cytometer. The Y-axis is 
read as the Logarithm of 647, and the X-axis is read as the DAPI Area. ~10,000 events were 








Sequence analysis of RNA was carried out as described in Chapter 2.  Most libraries 
were sequenced using an Illumina V3 flow cell using paired end 2 x 75 sequencing.  Data 




Characterization of TUT7 and 3’hExo KO Cells. 
To assess the role of TUT7 and 3’hExo on regulation of histone mRNA, I generated 
CRISPR-Cas9 knock out stable cell lines of each protein in HCT116 Colon Carcinoma cells. 
HCT116 cells are roughly diploid (Brattain et al., 1981), which limits the number of alleles 
that have to be targeted. Guide RNAs targeting the second exon of each protein were 
designed so they would disrupt the coding region early in the gene, and avoid possible 
alternative translation start sites (Fig. 3.2A,B). Two TUT7 knockout lines and multiple (>6) 
lines of 3’hExo were obtained.  
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Fig. 3.2. CRISPR KO Design and Validation. A. Guide RNAs (shaded) were targeted to the 
start of the gene, as close to the start codon as possible while being past alternative start 
codons. Two guides were used for TUT7, and one guide was used for 3’hExo. B. Detailed 
sequence of the guides (Green and Blue guides target antisense strand, Pink guide targets 
sense strand) and sequencing results of CRISPR KO’s. C,D. Western Blot screening for 
TUT7 and 3’hExo KO. E. Western Blot of for TUT4 in the TUT7 KO’s showing TUT4 
Expression Increases. Note that two forms of TUT4 were observed.  F. Control Western Blot 
to show TUT7 and 3’hExo expression are independent of each other 
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I obtained seven different knock out cell lines of 3’hExo.  In the initial first attempt 
with the single guide against 3’hExo I obtained one mutant cell line that was heterozygous. 
This clone was unaltered on one allele, and the other allele had a 20nt deletion, producing an 
indel that disrupted the reading frame (Fig. 3.1). When tested for expression, I confirmed that 
it produced about half as much 3’hExo as the wild type positive control. This 20nt deletion 
removed the PAM site and most of the guide sequence from the allele. This allowed me to  
use the same guide RNA on the new cell line without risking it targeting the already mutated 
allele, since it could only target the remaining wild type allele. This second round of CRISPR 
and colony selection was more efficient, and seven knockouts (out of ~30-40 cells analyzed) 
were identified in the second round of CRISPR.  Each had the 20nt deletion in one allele (as 
anticipated) and another novel indel that disrupted the reading frame. There was one clone 
that had the same 20nt mutation on the second allele, suggesting that homologous 
recombination was induced by the CRISPR-mediated cleavage, and the mutated allele was 
used as the donor template.  
 In a single CRISPR experiment for TUT7, I analyzed ~30 clones by Western blotting, 
and then sequenced the candidate clones, and obtained two knockout cell lines.  To identify 
the changes that occurred in each allele, I subcloned the PCR products of the targeted 
regions, and sequenced them. For detailed analysis, I focused on two knockout lines for each 
gene for biological replicates. The sequences of the disrupted alleles are shown in Fig. 3.2B.  
I confirmed the knockout of the targeted proteins by western blotting (Fig. 3.2C,D).  Note 
that we detect two species with the TUT7 antibody, which is made against the N-terminal 
region of the protein, and both of them are absent in the KO cell lines.  Whether these 
represent a proteolytic cleavage product or an alternatively spliced product is not known.  I 
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tested whether knockout of 3’hExo affected the expression of TUT7, and whether knockout 
of TUT7 affected the expression of 3’hExo or TUT4, a homologue of TUT7.  Knockout of 
TUT7 resulted in greatly increased expression of TUT4 protein in both of the knockout cell 
lines (Fig. 3.2E), suggesting that the increase in TUT4 might result in compensating for an 
essential function for cell growth of TUT7.  The levels of TUT7 or 3’hExo were not changed 
by knockout of the other protein (Fig. 3.2F). Note that TUT4 and TUT7 are very similar 
proteins, and in most studies they have been found to participate in uridylating similar 
targets, including let7 pre-miRNA (Faehnle et al., 2017; Thornton et al., 2014); defective 
structural RNAs (łabno et al., 2016); the degradation of vertebrate maternal mRNAs (Chang 
et al., 2018);  the oligoA tail remaining on deadenylated mRNAs (Lim et al., 2014); and 
degradation of mRNAs during apoptosis (Thomas et al., 2015).    
 
TUT7 and 3’hExo KO’s Affect the 3’ Termini of Histone mRNA 
To assay the effect of the knock out of TUT7 or 3’hExo on histone mRNA 
metabolism, I synchronized cells at the beginning of S-Phase using a double thymidine 
block. After releasing the cells into S-phase for three hours, I harvested the cells for RNA 
and used flow cytometry combined with EdU labeling to confirm they were in S-phase.  We 
then prepare EnD-Seq libraries as described in Chapter 2, using a strategy designed to 
determine the 3’ ends of the histone mRNAs, including identifying any nontemplated 
nucleotides. The resulting cDNA library (Holmquist and Marzluff, 2019; Slevin et al., 2014; 
Welch et al., 2015) was then sequenced to determine the 3’ termini of histone mRNAs and 
degradation intermediates with single nucleotide resolution (Fig. 3.3).  We show the results 
for two histone mRNAs, HIST2H2AA3 and HIST1H2BF.  Histone pre-mRNA is cleaved 5 
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nucleotides after the stem-loop in the nucleus.  The 3’ end of the histone mRNA is bound to 
SLBP and is trimmed by 2-3 nucleotides by 3’hExo which forms a complex on the 3’ end of 
the mRNA together with SLBP (Tan et al., 2013; Yang et al., 2006) (see Fig. 1.2).  If the 
3’hExo removes one or two additional nucleotides in wild-type cells, a TUTase adds 
nontemplated uridines to replace them, restoring the mRNA to 3 nucleotides after the 
stemloop (Lackey et al., 2016; Welch et al., 2015).  The data is displayed by indicating the 
position of the last template nt, with different colors indicating the addition of 0, 1, 2, or >2 
nucleotides at that position.  After trimming of the 3’ end by 3’hExo, the histone mRNA 3’ 
termini ends in ACC after the stem-loop (index 2), however if either one or two additional 
nucleotides are removed, then one or two uridines are added restoring the tail to 3nt past the 
stem-loop.  
 
Fig. 3.3. Wild 
Type Stable 
Termini A. Indices 
assigned to the 3’ 
end of histone 
mRNA counting up 
into the stemloop. 
B. Histone mRNA 
Libraries from Wild Type HCT116 cells synchronized at 3 hours into S Phase show 90+% of 
reads are at index 2,3,4 and maintain 3nt past the stem loop. Pie chart showing distribution 
of tails of indices 0-4.  
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Fig. 3.4. KO Cell’s Stable Termini A. TUT7 KO Library at 3 hours in S Phase have many 
shorter tails and reduced uridylation. B. 3’hExo KO Library at 3 hours in S Phase have 
many longer tails, most of which are due to non-templated nucleotides. C. Chart showing the 
data provided from pie charts and the percent of nontemplated tails that are uridines. N is 
either G or A. 
There were dramatic changes at the 3’ ends of histone mRNAs in both the 3’hExo 
and TUT7 KO cell lines (Fig. 3.4). In the TUT7 KO cell lines, fewer uridylated tails were 
present on the 3’ termini, with only about 20% as many non-templated nucleotides added, as 
in WT cells (Fig. 3.4A).  In addition only 80% of the non-templated tails were uridines 
compared with >98% in the wild-type cells (Fig. 3.4C).  This result demonstrates TUT7 is 
the primary protein responsible for adding uridines to the 3’ termini of histone mRNA. It is 
likely that TUT4, which is highly increased in the TUT7 KO cells, is responsible for the 
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addition of the remaining uridines in the absence of TUT7, and that TUT4 is much less 
efficient uridylating histone mRNAs than TUT7.   
The 3’ hExo cell lines demonstrate an opposite pattern from the TUT7 KO cells. 
There is still some trimming of the 3’ end, removing 1 or 2 nucleotides, presumably by other 
exonucleases, but there are also 3’ ends ending in ACCCA or ACCC (Fig. 3.4B).  There are 
no RNAs ending at these positions (0 and 1), in the wild type or TUT7 KO cells. The major 
difference in the 3’hExo KO cells is in the more extensive uridylation, with substantial 
amounts of ACCU and ACUU tails, suggesting that TUT7 is still recruited to the histone 
mRNA to uridylate the mRNA.  The data are consistent with TUT7 and 3’hExo acting 
together to maintain the 3’ end of 3 nucleotides tail past the stemloop.  If more uridines are 
added by TUT7, they are then likely removed by 3’hExo.    
More than 95% of the histone mRNAs in the wild-type cells end 3 nucleotides after 
the stemloop, either in ACC, ACU or AUU or 2 nucleotides ending in AC.  In contrast, in the 
3’hExo cells, a large fraction of the histone mRNAs are longer, either with uridines added at 
index 1 (ACCU) or multiple uridines added at index 2 (ACUU) (Fig. 3.4B), as well as longer 
untrimmed RNAs.   In the TUT7 KO’s a substantial fraction of the histone mRNAs have less 
than 3 nt tail due to failure to uridylate trimmed mRNA (Fig. 3.4A).   The TUT7 KOs also 
have a large number of RNAs with 1-3 nucleotides removed from the stem. Instead of 95+% 
of reads on indices 2-4 in wild type and 3’hExo KO cells, TUT7 KO’s have only 84% of 
reads on indicies 2-4, with more molecules ending at indices 5, 6, and 7 for HIST2H2AA3 
(Fig. 3.4C).  In the TUT7 KO cells, only 80% of the nontemplated nucleotides are uridine 
while in the WT and 3’hExo 93%+ are uridine (Fig. 3.4C).  Whether the presence of 
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nontemplated nucleotides other than uridine is due to errors in sequencing or addition of 
other nucleotides to the histone mRNA cannot be determined.  
 
Effect of KO of TUT7 or 3’hExo on Histone mRNA Degradation 
The 3’ end of histone mRNA is the element that determines rapid degradation of 
histone mRNA when DNA replication is inhibited (Pandey and Marzluff, 1987). The initial 
step in degradation is degradation into the stem (Hoefig et al., 2013; Mullen and Marzluff, 
2008) followed by extensive uridylation of nucleotides in the 3’ side of the stem (Meaux et 
al., 2018; Slevin et al., 2014).  To determine the effect of the knock outs on degradation, we 
treated the KO cell lines in mid-S-phase with hydroxyurea which inhibits 
deoxyribonucleotide reductase and stops DNA synthesis. This triggers the rapid degradation 
of histone mRNAs. We used northern blotting to visualize and quantify the degradation of 
the histone mRNA over the course of an hour. In WT cells the histone mRNAs are degraded 
rapidly, with 90% of the mRNA degraded in 40 min.  In TUT7 KO cells, the histone mRNAs 
were still degraded although the degradation rate was slower, with 25% of the histone mRNA 
remaining after 40 minutes (Fig. 3.5A). In contrast, in the 3’hExo KOs, histone mRNAs were 
stable, with no degradation even 40 minutes after treatment with hydroxyurea (Fig. 3.5A). 
These results show that 3’hExo is essential for rapid degradation of histone mRNA, as 
previously demonstrated by Hoefig et al. in fibroblasts from knockout mice (Hoefig et al., 






3’hExo and TUT7 KO’s Show Alterations in the Degradation Pathway 
 To assess the effect of the knockouts on the intermediates in histone mRNA 
degradation, we prepared EnD-Seq libraries after treatment of cells with hydroxyurea. In 
wildtype cells there are two predominant degradation intermediates that appear: the first is a 
result of degradation into the stem-loop while SLBP remains bound, and uridylation of those 
RNAs, and the second is intermediates that accumulate starting ~17nt 3’ of the stop codon 
when the exosome would contact a paused terminating ribosome (Fig. 3.5B) (Meaux et al., 
2018; Slevin et al., 2014).  Multiple intermediates are also detected as a result of further 
degradation into the ORF, which is still bound by ribosomes (Slevin et al., 2014).  Lsm1-7,   
which binds to the U-tails on the intermediates in the stem, is required for degradation of 
histone mRNA (Lyons et al., 2014; Mullen and Marzluff, 2008).  There are very few 
intermediates between these two primary sets of intermediates in wild type cells, suggesting 
that once degradation is initiated on the uridylated intermediates in the stem, the 3’ to 5’ 
degradation by the exosome of the 3’ UTR occurs very rapidly and processively.  There is 
extensive uridylation of both sets of intermediates in wild-type cells, with long U-tails (>5 
nucleotides) accumulating primary on the two G’s (index 7 and 9) on the 3’ side of the 
stemloop (Fig. 3.5C), as well as uridylation of the intermediates near the stop codon and in 
the ORF (Fig. 3.5D), although these tails are not as long as the ones added to the stem. 
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Fig. 3.5. HU Mediated Degradation of Knock Out cell lines. A. Northern Blot of H2A mRNA 
after cells are treated with Hydroxyurea (in minutes) after synchronization 3 hours past the 
start of S Phase. B. The two main degradation intermediates seen in 3’ to 5’ degradation 
pathway of histone mRNA. The first is the stemloop intermediate, where SLBP on the 5’ side 
blocks degradation down the stem, and the second is the Stop Codon intermediate, where a 
paused ribosome blocks the exosome. C. Stem Loop Intermediate graphs highlighting index 
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5-20 show build up of intermediates in the TUT7 KO and reduced amount of degradation 
intermediates in the 3’hExo KO. D. Similar to C, showing Stop Codon Intermediates. 
In the TUT7 knockouts the pattern of degradation intermediates is strikingly different.  
In contrast to the reduced uridylation on the 3’ end of histone mRNA (Fig. 3.4B), there are 
almost no uridylated intermediates in the stem compared with the wild-type RNA, with only 
small amounts of primarily monouridylation at positions 7, 8 and 9 (Fig. 3.5C).  There are 
many more intermediates resulting from degradation further into the stem, which also are not 
uridylated, and are not present in RNA from wild-type cells.  There are three times as many 
intermediates in the stemloop, as in wild-type cells, suggesting that the lack of uridylation 
results in failure to rapidly degrade throughout the stemloop.  
In contrast in the 3’ hExo knockouts there were only small amounts of intermediates 
(Fig. 3.5E) resulting from degradation into the stemloop. These were heavily uridylated.   
The nuclease responsible for this degradation is not known.  The most striking difference is 
the lack of degradation intermediates between the stemloop and the rest of the mRNA.  
Clearly the step that allows degradation to proceed past the 3’ side of the stem is impaired in 
the 3’hExo mutants, shown by half as many 3’ UTR degradation intermediates, suggesting 
3’hExo may also play an active role in this process.  
 
Hydroxyurea Induced Degradation Mimics Natural Degradation at the End of S-phase 
 Our lab has used hydroxyurea treatment as a means to initiate rapid degradation of 
histone mRNA in human cancer cells for years. It has been useful for studying degradation of 
histone mRNA in cells that cannot be synchronized, such as knock down cells. Using a 
double thymidine block, I synchronized wild type cells to the beginning of S-Phase and 
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released them. I treated the cells in the middle of S-Phase (3 hours) with HU to initiate 
histone mRNA degradation (Fig. 3.6A) and also took RNA samples from the cells at the end 
of S-Phase (Fig. 3.6B,C). I compared the degradation intermediates (stemloop and stop 
codon) of the HU treated cells versus the naturally degraded histone mRNA at the conclusion 
of S-Phase (Fig, 3.6D,E). A similar set of intermediates is seen at the end of S-phase, with 
the most uridylation at nts 7-9.  The distribution of length of the U-tails is similar to the S-
phase cells treated with HU. This demonstrates that the pathway of histone mRNA 
degradation is the same in S-phase cells with DNA synthesis inhibited, as in cells at the end 
of S-phase.   
Fig. 3.6. Hydroxyurea 
Mimics the Degradation 
of Histone mRNA at the 
end of S-Phase. A. 
Northern Blot of Wild type 
RNA samples from cells 
treated with HU over the 
course of 40 minutes show 
rapid histone mRNA 
degradation. B. Northern 
Blot of RNA from Wild 
Type cells taken hours 




degradation approximately 7 hours after S-Phase begins.  C. Flow Cytometry with EdU 
staining of Wild Type cells confirms cells exit S-Phase approximately 7 hours after S-Phase. 
D,E. Comparing Stemloop and Stop Codon degradation intermediates of HU treated and 
naturally degrading histone mRNA show similar patterns and levels. 
 
3’hExo KO’s have a Cell Cycle Defect 
Degradation intermediates taken at the end of S Phase are comparable to degradation 
intermediates induced by hydroxyurea treatment on synchronized cells in S Phase, both in 
regard to uridylation pattern and in relative distribution of where intermediates appear. We 
tested whether the 3’hExo and TUT7 KO’s also had effects on degradation of histone mRNA 
at the end of S-phase.  We synchronized cells by double-thymidine block and determined the 
progression of cells through S-phase by measuring DNA content as well as by labeling cells 
for 30 minutes with EdU prior to harvesting to determine the rate of DNA synthesis.  Both 
the wild-type cells and TUT7 KO’s went through S-phase with similar kinetics (Fig. 3.7A).  
Histone mRNA levels were high in mid-S phase and declined as cells exited S-phase (Fig. 
3.7B).  The distribution of cells in different cell cycle stages was similar in the WT and 
TUT7 knockout cells.  However, the levels of histone mRNA declined more slowly than in 
TUT7 KO cells than in wild-type cells (Fig. 3.7B), consistent with the slower rate of 
degradation of histone mRNA seen in these cells after treatment with inhibitors of DNA 
replication in S-phase.  
In contrast to the TUT7 KO cells, the 3’hExo cells progressed more slowly though S-
phase.  They were still in S-phase at 9 or 10 hours and didn’t undergo mitosis until 12 hrs, 
about 2 hours later than the TUT7 KO cells.   Although the 3’hExo KO cells were delayed in 
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leaving S-Phase, and histone mRNA is not degraded in these cells even after 40 min of 
inhibition of DNA synthesis, the histone mRNA was still reduced to very low levels before 
the cells entered G1 (Fig. 3.7B).  Histone mRNA degradation is initiated later in 3’hExo cells 
(relative to the end of S-phase) than in wild-type.   Both with HU treatment and by end of S 
Phase, the 3’hExo KO cells struggle to initiate degradation of the histone mRNA.  
To analyze 3’ to 5’ degradation in cells at the end of S-phase, we analyzed 
degradation intermediates in the TUT7 KO cells at the end of S-phase. Wild type cells 
exiting S-phase 6 to 7 hours after release from the double thymidine block showed very 
similar degradation patterns to the hydroxyurea degraded samples (Fig. 3.6).  The TUT7 KO 
cell lines exiting S-phase at 7 hours also showed a similar pattern of degradation 
intermediates with almost no uridylation, and more intermediates through the stemloop and 
into the 3’ UTR, as was found after inhibition of DNA replication (Fig. 3.7D). The 3’hExo 
cells exiting S-Phase/inG2 around 10 hours (Fig. 3.7E), also mimicked the small amount of 
degradation intermediates restricted to degradation into the stem and uridylation of these 
intermediates seen in these cells when DNA replication is inhibited, which do not result in 
rapid degradation of histone mRNA.  These data strongly suggest that a different pathway 
leading to degradation in G2 cells in the 3’hExo KO cells could be present, which is not 
necessarily when DNA replication is inhibited in S-phase.  This pathway likely involves 
either 5’ to 3’ degradation or endonucleolytic cleavage, pathways that are not utilized in S-




Fig. 3.7. Natural 
End of S-Phase 
Degradation. A. 
EdU/DAPI 




TUT7 KO’s pass 
through S Phase 
into G2 at the 
same time as 
Wild Type cells, and that 3’hExo KO’s are delayed in S Phase by ~2 hours. B. Northern Blot 
of H2A mRNAs taken hours past the start of S Phase. TUT7 KO’s histone mRNA degradation 
is delayed 1-2 hours past Wild Type. 3’hExo KO’s histone mRNA degradation is stalled until 
shortly before Mitosis at 12 hours. C,D,E . Stemloop and Stop Codon Degradation 
Intermediates at the end of S Phase for Wild Type (C), TUT7 KO (D), and 3’hExo KO (E).  
 
Changes in Tail Length and Degradation Intermediate Distributions in 3’hExo KO’s 
 Studying the 3’hExo KO libraries, we see that there is extensive monouridylation on 
indices 0 and 1, and small amounts of oligouridylation (Fig. 3.8A). These are the nucleotides 
that are normally removed by 3’hExo from 5nt down to 3nt past the stemloop. This suggests 
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that TUT7 is still recruited to uridylate the histone mRNA without trimming after processing.  
There is no change in this pattern in G2 phase in the 3’Exo KOs. 
If we look at the tail length distribution on indices 7-9, we see that longer tails are 
prevalent, going up to 7nt long, even in the 3’hExo KO’s (Fig. 3.8B). These patterns are 
again similar in both the HU treated cells and natural end of S-Phase cells. This suggests that 
7-9 are preferred for long tailing, and the tails may have to get long enough to bind Lsm1-7 
before degradation can proceed further.  Although these tailed intermediates form in the 
3’hExo KO, there are many fewer intermediates than in the wild type, and these 
intermediates likely don’t give rise to efficient degradation, suggesting 3’hExo may be 
involved in proceeding into productive degradation.   
Index 5 is unique, in wild type cells, in that it has a large percentage of 3-4 nt tails, 
restoring “normal” histone tail length (Fig. 3.8C) in S-phase. Also, note the majority of the 
Index 5 reads are untailed or monouridylated, suggesting it is some form of pause site before 
degradation into the 3’ stemloop. When degraded with HU, the number of longer tails 
decreases, preferring to not add tail. Both the 3’hExo and TUT7 KO’s  also respond by 
increasing this untailed population, and reducing the 3nt and 4nt tails (maintaining or 
extending) suggesting both KO’s and wild type cells may pause at the index 5 form during 
degradation.  
When we look at either the stable 3’ termini or the two degradation intermediates, we 
note that 3’hExo KO cells have a much lower percentage of degradation intermediates 
whether in S-Phase or being degraded compared to wild type or TUT7 KO cells (Fig. 3.8D). 
The wild type cells during degradation (either HU or natural S-Phase) increase the number of 
intermediates compared to non-degrading, as expected. TUT7 KO cells similarly increase the 
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number of degradation intermediates during degradation, however there is a significant 
increase in the relative number of stop codon intermediates for the natural end of S Phase 
(green bar), whereas the HU treatment (red bar) prefers the stemloop degradation 
intermediate (Fig. 3.8D). This is the only noticeable difference detected between HU 
treatment and natural degradation at the end of S-Phase, and only within the TUT7 KO cells. 
 
Fig. 3.8. Graphs of Index Specific Tail Lengths and degradation intermediate distribution. A. 
Nontemplated tail lengths on Index 0 and 1 (ACCCA and ACCC) in 3’hExo KO’s. B. 
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Nontemplated tail lengths on Index 7 and 9 in 3’hExo KO’s (above) and Wild Type (below). 
C. Nontemplated tail lengths on Index 5 in 3’hExo KO’s (above) and Wild Type (below). D. 
Percent Distribution of Stable 3’ termini (Index 0-5), Stem Loop Degradation Intermediates 
(6-26), and Stop Codon Degradation Intermediates (27-100) for Mid S-Phase (blue), HU 
Treatment Degradation (red) and natural S-Phase degradation (green). For the Wild Type, 




TUT7 and 3’hExo Work Together to Maintain 3’ End of Histone mRNA 
 Previous work in the lab has suggested that a TUTase and 3’hExo work together to 
maintain the 3’ end of histone mRNA, with TUT7 by adding uridines that are removed by 
3’hExo.  RNAi experiments showed a larger effect on the 3’ end by TUT7 knockdown than 
TUT4 knockdown. However, in RNAi experiments there is always residual amount of the 
target protein, making it impossible to determine the amount of uridylation carried out by a 
particular TUTase.  In addition, we did not know whether KO of TUT7 might interfere with 
cell growth,  To determine the precise roles of TUT7 and 3’hExo, CRISPR knock outs were 
made, and these confirmed the general conclusions based on RNAi in the  previous study  by 
Pat Lackey in our lab (Lackey et al., 2016). 
 
Maintaining the Steady-State that Leaves 3nt Past the Stemloop on Histone mRNA 
It is not known why histone mRNA is trimmed to two to three nucleotides past the 
stemloop.  However, it is likely important to maintain that length for optimal binding of 
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SLBP and stability of histone mRNA.  Uridylation of the 3’ end allows the cell to restore the 
length of the 3’ end.  The TUT7 KO cells have an ~80% reduction of uridylation at the 3’ 
end, resulting in significantly shorter tails during S-Phase. Thus, TUT7 is the major TUTase 
responsible for adding non-templated tails to the 3’ termini to maintain histone mRNA. 
Surprisingly both independently derived TUT7 KO cell lines, had a large increase in TUT4 
levels suggesting that there are critical functions of TUT7 in HCT116 cells which can only 
be covered by increasing TUT4 concentrations.  TUT4, while overexpressed and commonly 
implicated with TUT7 in other regulation pathways, was not sufficient to maintain tail 
lengths on histone mRNAs comparable to wild type cells.  These results, in agreement with 
the previous RNAi of TUT4 showing little effect on histone mRNA tails (Lackey et al., 
2016), demonstrates that TUT7 and TUT4 have differentiated activities in some metabolism 
pathways for RNA. 
3’hExo also participates in regulating this 3 nucleotide termini length by initially 
trimming the processed histone mRNA from 5nt past the stemloop to 3nt past the stemloop 
(Yang et al., 2006). The knock out data shown here confirms this, with the 3’hExo KO cells 
having untrimmed 3’ termini extending four or five nucleotides past the stemloop. However, 
there is still trimmed 3’ termini, suggesting that some other exonuclease(s) are able to 
perform the same role as 3’hExo, albeit much less efficiently. It is likely that the 
exonucleases that trim the 3’ termini in the 3’hExo KO cells are transient and are not 
necessarily bound to the 3’ termini like 3’hExo binds to the stemloop (Yang et al., 2006). 
TUT7 can still uridylate the 3’ ends of histone mRNAs (even on tails longer than 3 nts) in the 
absence of 3’hExo.  Thus, TUT7 is likely recruited to histone mRNAs largely by the 
SLBP/SL complex and not 3’hExo.  Between the combined activities of 3’hExo removing 3’ 
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nucleotides and TUT7 adding nontemplated uridines, we can conclude that these two 
enzymes work together to maintain the 3’ termini as seen in wild type cells.  
 
3’hExo Initiates and TUT7 Increase the Rate of Degradation of Histone mRNA 
 The precise molecular signals that result in initiation of 3’ to 5’ degradation of histone 
mRNA are still largely unknown. However, the knock out cells generated in this dissertation 
prove that 3’hExo is required for initiation of degradation, since without it in the 3’hExo KO 
cells, we see drastically fewer degradation intermediates, and there is essentially no rapid 
degradation of histone mRNA when DNA replication is inhibited.  
The intermediates that are observed are similar in both form and uridylation pattern to 
the wild type cells, just at drastically lower levels. How these intermediates are generated in 
not known, but they are not present in S-phase cells. There must be other exonucleases that 
can digest into the stemloop once DNA replication is inhibited, possibly a result of changes 
in the SLBP/SL structure at the 3’ end of the mRNA.  These intermediates are present in low 
levels.  This suggests that 3’hExo is not necessarily required for processive degradation, but 
rather at beginning the degradation pathway by degrading up into the stemloop. What signals 
3’hExo to begin degrading further up into the stemloop is still unknown. 
 The TUT7 KO cells, on the other hand, struggle to maintain processivity of 
degradation. The TUT7 KO cells have a large amount of degradation intermediates not just 
in the stemloop or at the stop codon, but all through the 3’ UTR for multiple histone genes. 
Short oligouridine tails have been shown to bind Lsm1-7, which can then recruit the 
decapping machinery or the exosome, and if the uridine tails are not present, the histone 
mRNA may have trouble starting the 3’ to 5’ degradation (Tharun et al., 2000). In addition, 
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the efficiency of the exosome may be poor, so that TUT7 is required to uridylate through the 
UTR as part of some 3’ machinery to keep the exosome on target until it conflicts with the 
stop codon. There is a rather large pause in the middle of the 3’ UTR as well, which is unique 
to HIST2H2AA3, which as a very GC rich 3’ UTR.  which could be an endonucleatic 
cleavage site and could provide a possible alternative degradation pathway, such as NMD.  
 
TUT7 KO’s do not Delay S-phase, but do have a Delay in Degradation of Hstone 
mRNA. 
 One of the largest advantages, for our purposes, Knock Out cells offer over Knock 
Down is the ability to synchronize the knock out cells. This gives us the opportunity to study 
the effect of the protein on the cell cycle, which is monumental to replication-dependent 
histone mRNA metabolism. The TUT7 KO Cells do not have a delayed S-Phase, and mimic 
wild type in the transition from S-Phase to G1, as shown by the EdU and DNA staining flow 
cytometry data. However, the TUT7 KO cells do show a delay in histone mRNA 
degradation. Continuing to take RNA samples after the start of S-Phase, we see that in wild 
type cells, histone mRNA levels drop around 7 hours past the start of S-Phase, which is about 
when S-Phase ends. In the TUT7 KO cells, the histone mRNA continues to linger one or two 
hours past the end of S-Phase. This suggests that the KO cells struggle to degrade the histone 
mRNA, which is suggested by the copious degradation intermediates in the 3’ UTR of the 
libraries. The cell cycle is likely unaffected as while degradation is slow, it still proceeds, 
which includes overcoming the first degradation intermediate, the stemloop. For this 
intermediate, SLBP must be removed, and later degraded. Without SLBP bound to the 
stemloop, the histone mRNA can no longer be circularized and translated, effectively 
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stopping the production of histone proteins. So, while the histone mRNA molecule continues 
to linger during a slower degradation process, its function is essentially over. The cell can 
continue normally through the cell cycle after DNA replication ends.  
 
3’hExo KO’s Delay S-phase, and Histone mRNA Degradation is Delayed until Mitosis. 
 The 3’hExo KO Cells do have a delay in the cell cycle. In coordination with EdU and 
DNA Staining data, I observed the 3’hExo cells remain in S-phase approximately two hours 
longer than wild type or TUT7 KO cells. Mitosis was observed at 12 hours (the rounding up 
of the cells), instead of 10 hours as it was in Wild Type or TUT7 KO cells, suggesting that 
G2 and mitosis are unaffected. This delay of S-Phase is also linked with the histone mRNA 
levels. When RNA samples were taken over the course of the cell cycle, we see that histone 
mRNA levels are maintained, much as they are when treated with HU. The histone mRNA 
levels finally drop at the very end of S-Phase, around 10 hours, just before the cells go 
through G2/Mitosis. When looking at HU and natural end of S-Phase libraries, we see that 
the vast majority of molecules are unable to make it past the stemloop, suggesting that SLBP 
is still bound and thus producing histone protein. 
 The 3’hExo KO cells must find a path of degradation for the histone mRNA by the 
conclusion of S-Phase, but the path is still largely unknown. Previous work in the lab has 
shown that histone mRNA’s are sometimes decapped, which allows for the 5’ to 3’ 
degradation pathway (Mullen and Marzluff, 2008). In addition, our lab has shown that UPF1 
binds the 3’ UTR of histone mRNA, and could allow for Nonsense Mediated Decay (Meaux 
et al., 2018). However, without further study, the actual process of degradation for the 
3’hExo KO cell’s histone mRNA is still a mystery. 
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Degradation by Hydroxyurea Mimics the End of S Phase 
One of the questions our lab has asked is whether the treatment of hydroxyurea truly 
mimics natural degradation of histone mRNA at the end of S-Phase. When cells are treated 
with hydroxyurea, Deoxyribonucleotide reductase is inhibited. This limits the pool of dNTPs 
available, and signals the cell to stop DNA synthesis. At the same time, the cell triggers 
degradation of histone mRNA. My work shows that the degradation pattern triggered by HU 
matches that of the natural end of S-Phase (Fig 16). When comparing Wild type and TUT7 
KO’s, all have similar degradation distributions and uridylation patterns when comparing 20 
minutes of HU treatment of synchronized cells with cells that are natural exiting S-Phase, 
even across multiple H2A and H2B genes. This suggests that HU is a viable mimic for 
natural degradation of histone mRNA  3’hExo KO’s lack of degradation with HU, but by the 
end of S-Phase suggests another pathway is found that does not coordinate with normal 
inhibition of DNA synthesis triggered checkpoint. Longer HU treatments could shed some 
light on this, but for now it seems the cell finds another method of degrading histone mRNA 
















 The development of massively parallel sequencing over 10 years ago has led to the 
deep sequencing technology achieving deeper and more expansive views of genetic material 
every year. What was once impossible as little as 10 years ago is now a daily routine in many 
labs. Our lab broke new ground for deep sequencing histone mRNA transcripts with the 
development of the EnD-Seq/AppEnd library preparation and workflow, which allowed us to 
determine the 3’ end of mRNA including determining any non-templated nts present at the 3’ 
end. This gave us enormous insight to the 3’ termini of histone mRNA’s to better understand 
how they are processed and degraded.  Part of the work I presented monopolized on this to 
use a new kit from Illumina that has the same amount of chemistry as previous kits our lab 
used, but shorter reads allow for up to ~30 million reads per kit. This gave me up to three 
times the read depth per sample and a reliably clearer view of what is happening in rare RNA 
intermediates, such as the 3’hExo KO’s 3’ terminal degradation intermediates. One of these 
rarer events that deep sequencing has illuminated is the non-templated addition of uridines to 
the 3’ termini of histone mRNA. Uridylation is readily present on histone mRNA, and on 
other mRNA’s it is found on oligoA tails. Before deep sequencing it may have been assumed 
to be a sequencing error before deep sequencing. With the advent of deep sequencing we 
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have been able to identify these non-templated nts with confidence, even if they are a 
relatively rare event. 
 Many of the non-templated nucleotides are added by the TENT family of enzymes, 
with uridines being added by TENT3A and TENT3B, which are TUTases (Terminal Uridyl 
Transferases), previously named TUT7 and TUT4. In this dissertation I have shown that 
TUT7, and not TUT4, is the major TENT responsible for addition of the non-templated 
uridines on the 3’ termini of histone mRNA. TUT7 works in synchrony with 3’hExo, a 3’ to 
5’ exonuclease, to maintain the 3’ tail of histone mRNA at a certain length past the stemloop. 
When degradation begins, this balance is disrupted, and we see more extensive degradation 
into the stemloop.  
Deep sequencing technology continues to advance, and new strategies to studying 
DNA and RNA match its pace. Modifications to existing protocols, such as Lexogen’s novel 
sequencing approaches, could allow us to identify new roles for TUT7 and 3’hExo within the 
knock out cell lines. New RNA targets and the functions of degradation/stabilization of RNA 




EnD-Seq can Identify and Highlight Rare Events in Histone mRNA metabolism 
 The EnD-Seq Deep Sequencing method developed by our lab gives highly detailed 
and thorough perspective on histone mRNAs, and potentially other targeted RNAs. The 
library preparation minimizes potential damage to the RNA molecules and preserves the 
modified 3’ termini. In addition, by using RNA specific primers, we can amplify large 
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amounts of specific molecules, giving extensive read depth to see all variants of the histone 
mRNA. This gives us great insight into how histone mRNA is being metabolized and what 
forms are predominant at each part of the molecules “life cycle.” I have then continued on to 
apply this technique to study the degradation and metabolism of histone mRNA during the 
cell cycle, using CRISPR Knock Outs. 
 
Hydroxyurea Treatment Mimics Natural End of S-Phase 
 Hydroxyurea has been used by the Marzluff lab for years to inhibit DNA synthesis in 
cells and then trigger the degradation of histone mRNA. However, until recently, we have 
never been able to explicitly show the degradation mechanism is comparable to cells exiting 
S-Phase and degrading histone mRNA. The degradation intermediates after 20 minutes of 
HU treatment all resemble those of cells exiting S-Phase. This applies to the distribution of 
degradation intermediates, relative amounts of intermediates, and uridylation pattern of 
intermediates. In addition, it was shown not only in wild type cells, but also in the TUT7 
Knock Outs and 3’hExo Knock Outs. We can now continue using HU as a reliable method of 
inducing histone mRNA degradation that is comparable to how the cell inherently performs 
the same task. 
 
TUT7 and 3’hExo Work Together to Maintain Histone mRNA Tails 
 Histone mRNA’s half-life increases up to an hour during S-Phase, and part of this is 
likely due to the maintenance of the 3’ termini of histone mRNA. My work has confirmed 
the results of Heissmeier et al, that suggested that 3’hExo is not only responsible for 
trimming histone mRNA to the proper length (2-3nt past the stemloop) but also for initiating 
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degradation up into the stem-loop (Hoefig et al., 2013). As a counterpoint to 3’hExo, TUT7 
is the TENT that adds non-templated uridines to the 3’ termini to replace nucleotides 
removed by 3’hExo. These two enzymes work in tandem to maintain the proper length past 
the stemloop. 
 
TUT7 and 3’hExo are Integral to 3’ to 5’ Degradation of Histone mRNA 
 At some point before the end of S-Phase, DNA replication is inhibited and begins the 
machinations for the initiation of degradation of histone mRNA. The TUT7 Knock Out cell 
lines presented here demonstrate, with a buildup of degradation intermediates in the stemloop 
and through the 3’ UTR, that TUT7 is instrumental in helping initiate histone mRNA 
degradation and maintaining degradation throughout the 3’ UTR past the stemloop, until it 
hits the stop codon’s paused ribosome. We believe that TUT7 adds sufficiently long uridine 
tails to bind the LSM1-7 complex, and then recruit the exosome. 3’hExo, conversely, appears 
to primarily be involved in the initiation of degradation of the histone mRNA. Few 
degradation intermediates appear past the loop, and the 3’hExo KO cells demonstrate a lack 
of degradation of the histone mRNA. This suggests that once degradation begins, the cell can 
rapidly degrade the histone mRNA, but initiating degradation remains the largest obstacle for 
3’hExo KO cells. 
 
3’hExo KO’s Exhibit Cell Cycle Defects 
 The TUT7 KO cells do not have any noticeable phenotype in the cell cycle. They 
proceed through S-Phase at the same rate as wild type cells. The only difference is that the 
TUT7 KO’s have lingering amounts of histone mRNA for 1-2 hours after S-Phase ends, 
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suggesting that the SL has been degraded, stopping translation, but slow degradation 
continues for several hours after. The 3’hExo KO’s, however, both exhibit delayed cell cycle 
phenotypes. The 3’hExo KO’s both have a lengthened S-Phase, by about two hours, where 
histone mRNA does not degrade. G2/M both seem to be the same rate as wild type. Histone 
mRNA is eventually degraded by the time the cells reach mitosis, but there are still reduced 
levels of degradation intermediates. This suggests that the cell has found a way to degrade 
histone mRNA that is not 3’ to 5’, and takes slightly longer. However, the 3’hExo KO’s still 




Deep Sequencing and Modified EnD-Seq can Identify New Non-templated Targets 
 One of the allures of EnD-Seq is that it provides the means to amplify gene-specific 
libraries that can study the 3’ termini down to single nucleotide resolution, accurately and as 
they appear naturally after terminal additions of nucleotides. We can add to this specificity 
by modifying the library preparation. With rRNA depletion and polyA- selection, we can 
enrich the RNA for messenger RNA that contains deadenylated tails. From here, we can use 
a novel 5’ cap-specific primer developed by Lexogen (Teloprime) in conjunction with our 3’ 
specific linker sequence to selectively amplify all mRNA that are deadenylated and remain 
capped. This process would give us greater insight into 3’ to 5’ degradation pathways for 
other mRNAs, along with any non-templated additions or removals to deadenylated mRNAs 
before degradation. Another approach would be to replace gene-specific 5’ priming in EnD-
Seq with random primers to amplify all RNAs selected for in the RNA sample preparation 
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(such as polyA+ or rRNA depletion). The limitations of this method would be the 
amplification of small, abundant RNAs, such as snoRNAs.  
 Another deep sequencing project to explore would be a transcriptome wide survey of 
the TUT7 knock outs and 3’hExo knock out cells lines, relative to the wild type progenitor 
line. TUT7, in particular, has been implicated in regulation of a variety of RNA regulatory 
systems such as let-7 miRNA and LINE-1 mRNAs (Heo et al., 2012; Warkocki et al., 
2018b), and the effects on those RNAs in the knock out are unknown. 3’hExo, on the other 
hand, is known to work on histone mRNA, 5.8S rRNA, and some miRNAs (Ansel et al., 
2008; Dominski et al., 2003; Thomas et al., 2012). A transcriptome wide deep sequencing 
experiment could reveal the potential effects/compensations of the knock outs on other 
RNA’s besides the histone mRNA.  
 
Alternative Pathways May Exist to Degrade Histone mRNA 
 In previous studies in the lab, histone mRNA has been shown to be degraded 3’ to 5’ 
and 5’ to 3’ independently of each other, albeit with a preference to begin degradation 3’ to 
5’ initially. There are other degradation pathways that could work on histone mRNA, such as 
decapping and 5’ to 3’ degradation, that could be explored. The 3’hExo knock outs, in 
particular, seem to be finding an alternative degradation pathway to degrade histone mRNA 
by the end of S-Phase. Studying possible decapping enzymes could highlight alternative 
pathways the histone mRNA is using to degrade after DNA synthesis is inhibited, either 





Alternative Targets of TUT7 and TUT4 
 As previously mentioned TUT4 and TUT7 are very similar in structure. They share 
the same catalytic domains, and both have expansive intrinsically disordered regions between 
these domains. They have also been shown to compensate for each other in vitro on let-7 
miRNA/pre-miRNA (Heo et al., 2012). However, previous work in our lab by Pat Lackey, 
along with my knock out cell lines, show that TUT7 targets histone mRNA, while TUT4 has 
no effect, and is overexpressed in compensation to a TUT7 knock out. This suggests that 
TUT7 and TUT4 may be able to compensate for each other to some degree, but that different 
TUTases are recruited to different RNA’s. To determine what these could be, we can study 
likely candidates with deep sequencing, such as the let-7 pre-miRNA, in the TUT7 knock out 
to see if the uridylation activity has changed at all in regards to the lack of TUT7 or the 
drastic increase of TUT4. In addition, we can identify other targets of TUT7 or TUT4 by 
looking at a transcriptome wide deep sequencing screen of the TUT7 KO cells to identify any 
changes in expression of various RNA’s and potential isoforms. Another alternative approach 
would be rescuing the TUT7 knock out with a TUT7 cDNA construct, initially wild type but 
later modified to share a TUT4 disordered domain, to identify RNA’s that change expression 
from the TUT7KO to the rescue form. The disordered domain swapping of TUT7 and TUT4 
in a rescue could help highlight if these long regions in between and on the ends of the 
catalytic domains provide any specificity to each protein.  
 
How Does TUT7 Recognize the Histone mRNP 
 It has been clearly shown that TUT7, and not TUT4, is responsible for uridylating the 
histone mRNA. However, we still do not know how TUT7 effectively recognizes the histone 
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mRNP, while TUT4 cannot. This could be tested with domain swapping TUT7 and TUT4. 
Both proteins share the same catalytic regions, but the intrinsically disordered regions 
between are unique (Fig. 1.6). I theorize that these regions are integral in target specificity for 
each protein. To test, we could swap TUT7 N-term, C-term, and middle intrinsically 
disordered regions with TUT4 counterparts, and then express these in the TUT7 KO. This 
could determine if certain regions are enough to rescue uridylation activity, and what regions 
are superfluous.  
 Another question regarding TUT7 specificity is whether TUT7 and 3’hExo both work 
together on any other RNAs. They seem to function on the histone mRNA by adding and 
removing at a similar catalytic rate, although this is still experimentally unknown. Either with 
a double knock out of TUT7/3’hExo (which may very well be lethal), or by carefully 
comparing the RNA expression changes in each knock out to each other and a wild type 
sample (such as with a Principle Component Analysis), we may be able to identify any other 
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